WO2009108760A2 - Dendritic macroporous hydrogels prepared by crystal templating - Google Patents

Dendritic macroporous hydrogels prepared by crystal templating Download PDF

Info

Publication number
WO2009108760A2
WO2009108760A2 PCT/US2009/035257 US2009035257W WO2009108760A2 WO 2009108760 A2 WO2009108760 A2 WO 2009108760A2 US 2009035257 W US2009035257 W US 2009035257W WO 2009108760 A2 WO2009108760 A2 WO 2009108760A2
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
crystal
hydrogel
mixture
urea
Prior art date
Application number
PCT/US2009/035257
Other languages
French (fr)
Other versions
WO2009108760A8 (en
WO2009108760A3 (en
Inventor
Christine Schmidt
Scott Zawko
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Priority to US12/919,667 priority Critical patent/US8668863B2/en
Publication of WO2009108760A2 publication Critical patent/WO2009108760A2/en
Publication of WO2009108760A3 publication Critical patent/WO2009108760A3/en
Publication of WO2009108760A8 publication Critical patent/WO2009108760A8/en
Priority to US13/909,707 priority patent/US8728499B2/en
Priority to US14/277,170 priority patent/US9320827B2/en
Priority to US15/135,978 priority patent/US9896561B2/en
Priority to US15/890,719 priority patent/US10442911B2/en
Priority to US16/597,106 priority patent/US10982068B2/en
Priority to US17/231,653 priority patent/US11760858B2/en
Priority to US18/361,981 priority patent/US20230383086A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J9/00Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
    • C08J9/26Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a solid phase from a macromolecular composition or article, e.g. leaching out
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0095Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52Hydrogels or hydrocolloids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/0052Preparation of gels
    • B01J13/0065Preparation of gels containing an organic phase
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/00272-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0045Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08HDERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00Macromolecular products derived from proteins
    • C08H1/06Macromolecular products derived from proteins derived from horn, hoofs, hair, skin or leather
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00Processes of treating or compounding macromolecular substances
    • C08J3/02Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075Macromolecular gels
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00Processes of treating or compounding macromolecular substances
    • C08J3/24Crosslinking, e.g. vulcanising, of macromolecules
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00Processes of treating or compounding macromolecular substances
    • C08J3/28Treatment by wave energy or particle radiation
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J5/00Manufacture of articles or shaped materials containing macromolecular substances
    • C08J5/04Reinforcing macromolecular compounds with loose or coherent fibrous material
    • C08J5/10Reinforcing macromolecular compounds with loose or coherent fibrous material characterised by the additives used in the polymer mixture
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J5/00Manufacture of articles or shaped materials containing macromolecular substances
    • C08J5/18Manufacture of films or sheets
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00Use of organic ingredients
    • C08K5/0008Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/0025Crosslinking or vulcanising agents; including accelerators
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00Use of organic ingredients
    • C08K5/0008Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/0083Nucleating agents promoting the crystallisation of the polymer matrix
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00Use of organic ingredients
    • C08K5/16Nitrogen-containing compounds
    • C08K5/21Urea; Derivatives thereof, e.g. biuret
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/04Alginic acid; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/10Heparin; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16Cyclodextrin; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00Compositions of proteins; Compositions of derivatives thereof
    • C08L89/04Products derived from waste materials, e.g. horn, hoof or hair
    • C08L89/06Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin, e.g. gelatin
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2201/00Foams characterised by the foaming process
    • C08J2201/04Foams characterised by the foaming process characterised by the elimination of a liquid or solid component, e.g. precipitation, leaching out, evaporation
    • C08J2201/042Elimination of an organic solid phase
    • C08J2201/0424Elimination of an organic solid phase containing halogen, nitrogen, sulphur or phosphorus atoms
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2205/00Foams characterised by their properties
    • C08J2205/02Foams characterised by their properties the finished foam itself being a gel or a gel being temporarily formed when processing the foamable composition
    • C08J2205/022Hydrogel, i.e. a gel containing an aqueous composition
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2205/00Foams characterised by their properties
    • C08J2205/04Foams characterised by their properties characterised by the foam pores
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2207/00Foams characterised by their intended use
    • C08J2207/10Medical applications, e.g. biocompatible scaffolds
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2305/00Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2305/00Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
    • C08J2305/04Alginic acid; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2305/00Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
    • C08J2305/08Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00Processes of treating or compounding macromolecular substances
    • C08J3/24Crosslinking, e.g. vulcanising, of macromolecules
    • C08J3/242Applying crosslinking or accelerating agent onto compounding ingredients such as fillers, reinforcements
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00Processes of treating or compounding macromolecular substances
    • C08J3/24Crosslinking, e.g. vulcanising, of macromolecules
    • C08J3/26Crosslinking, e.g. vulcanising, of macromolecules of latex

Definitions

  • the present invention relates in general to the field of hydrogels, and more particularly, to dendritic macroporous hydrogels prepared by crystal templating.
  • Hydrogels are generally polymer chain networks that are water-insoluble, but that absorb water. Often described as being “superabsorbent,” hydrogels are able to retain up to 99% water and can be made from natural or synthetic polymers. Often, hydrogels will have a high degree of flexibility due to their high water content. Common uses for hydrogels include: sustained drug release, as scaffolds (e.g., in tissue engineering), as a thickening agent, as a biocompatible polymer, in biosensors and electrodes and for tissue replacement applications. Natural hydrogels may be made from agarose, methylcellulose, hyaluronic acid (HA), and other naturally-derived polymers.
  • HA hyaluronic acid
  • a low-odor hydrogel-forming acrylic acid polymer is prepared by preparing a polymeric hydrogel by free-radically polymerizing a monomer composition comprising at least 50% by weight of acrylic acid in an aqueous polymerization medium and converting said hydrogel into a particulate hydrogel or into hydrogel-forming powder; and optionally treating the particulate hydrogel or said hydrogel-forming powder with a crosslinking substance which, actually or latently, contain at least two functional groups capable of reacting with the carboxyl groups on the addition polymer; characterized by the acrylic acid used in step (a) containing less than 400 ppm of acetic acid and propionic acid.
  • an organic/inorganic hybrid hydrogel is said to have superior homogeneity, transparency, mechanical properties, and swelling and shrinking properties.
  • a dry body of the organic/inorganic hybrid hydrogel is obtained by removing water from said hydrogel.
  • the organic/inorganic hybrid hydrogel comprises a water soluble polymer (A), a water swelling clay mineral (B) which can be homogeneously dispersed in water, and water (C), and water (C) is included in a three-dimensional network formed by (A) and (B).
  • the present invention includes a method of making a porous hydrogel by preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel; drying the cast mixture to form an amorphous hydrogel film; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the polymer around the crystal structure under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel.
  • the method further includes seeding the cast mixture with a seed crystal, e.g., of the crystallizable molecule.
  • the polymer is nucleic acids, amino acids, saccharides, lipids and combinations thereof, in monomeric, dimeric, trimeric, oligomeric or polymeric forms.
  • the polymer used in the method is selected from the group consisting of collagen, chitosan, gelatin, pectins, alginate, hyaluronic acid, heparin and mixtures thereof.
  • the polymer is a biopolymer, which may be, e.g., natural, synthetic or even synthetic and natural.
  • the polymer may be gelled by a chemical crosslink, a physical crosslink, or a combination.
  • the crosslink is induced by UV, temperature, pH, an ion, or ion-radical based methods or combinations thereof.
  • crystallizable molecules include: a small organic molecule selected from urea, beta cyclodextrin, glycine and guanidine or a salt such as potassium dihydrogen phosphate.
  • the method may further comprise adding a cross-linking agent to the mixture, the crosslinking agent selected from group consisting of p-Azidobenzoyl hydrazide, N-5-Azido-2-nitrobenzoyloxsuccinimide, disuccinimidyl glutamate, dimethyl pimelimidate-(2)HCl, dimethyl suberimidate-2 HCl, disuccinimidyl suberate, bis[sulfosuccinimidyl suberate], 1 -ethyl-3-[3-dimethylaminopropyl]carbodiimide-HCl, isocyanate, aldehyde, glutaraldehyde, paraformaldehyde and derivatives thereof.
  • a cross-linking agent selected from group consisting of p-Azidobenzoyl hydrazide, N-5-Azido-2-nitrobenzoyloxsuccinimide, disuccinimidyl glutamate, dimethyl pi
  • the crystal structure forms a lattice structure and supports the polymer during the crosslinking step.
  • the step of growing the crystal structure is by seeding the mixture with a crystal.
  • the step of growing occurs by spontaneous crystal formation, e.g., during the step of drying the cast mixture.
  • the present invention includes a porous hydrogel made by a method that includes preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel; drying the cast mixture to form an amorphous hydrogel film; seeding the cast mixture with a seed crystal of the crystallizable molecule; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the polymer around the crystal with a crosslinking agent under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel.
  • the polymer is nucleic acids, amino acids, saccharides, lipids and combinations thereof, in monomeric, dimeric, trimeric, oligomeric or polymeric form.
  • the polymer is selected from the group consisting of collagen, chitosan, gelatin, pectins, alginate, hyaluronic acid, heparin and mixtures thereof.
  • the polymer is a biopolymer, which may be, e.g., natural, synthetic or even synthetic and natural.
  • the polymer may be gelled by a chemical crosslink, a physical crosslink, or a combination.
  • the crosslink is induced by UV, temperature, pH, an ion, or ion-radical based methods or combinations thereof.
  • crystallizable molecules include: a small organic molecule selected from urea, beta cyclodextrin, glycine and guanidine or a salt such as potassium dihydrogen phosphate.
  • the method may further comprise adding a cross-linking agent to the mixture, the crosslinking agent selected from group consisting of p-Azidobenzoyl hydrazide, N-5- Azido-2-nitrobenzoyloxsuccinimide, disuccinimidyl glutamate, dimethyl pimelimidate- (2)HC1, dimethyl suberimidate-2 HCl, disuccinimidyl suberate, bis[sulfosuccinimidyl suberate], l-ethyl-3-[3-dimethylaminopropyl]carbodiimide-HCl, isocyanate, aldehyde, glutaraldehyde, paraformaldehyde and derivatives thereof.
  • a cross-linking agent selected from group consisting of p-Azidobenzoyl hydrazide, N-5- Azido-2-nitrobenzoyloxsuccinimide, disuccinimidyl glutamate, dimethyl pimel
  • the crystal structure forms a lattice structure and supports the polymer during the crosslinking step.
  • the step of growing the crystal structure is by seeding the mixture with a crystal.
  • Another embodiment of the present invention is a hydrogel that includes molecular pores, the hydrogel having one or more crosslinked polymers formed about a plurality of preformed molecular crystals, wherein the crystals are formed while the polymer is in uncrosslinked form and the molecular crystals form a porous structure within the polymers during crosslinking of the polymers.
  • FIGURE 1 shows the chemical structures of biopolymers used in these hydrogels and a schematic of the crystal-templating technique
  • FIGURES 2A to 2F are polarized light (FIGURES 2A and 2D) and phase contrast (FIGURES 2B, 2C, 2E, and 2F) microscopy images of crystal templated HA hydrogel;
  • FIGGURE 2A polarized light microscopy image of uncrosslinked HA hydrogel-urea crystal composite;
  • FIGGURE 2B phase contrast microscopy image of uncrosslinked HA hydrogel-urea crystal composite;
  • FIGGURE 2C phase contrast microscopy image of crosslinked HA hydrogel after removal of the urea crystals;
  • FIGGURE 2D polarized light microscopy image of uncrosslinked HA hydrogel-urea crystal composite;
  • FIGURE 2E phase contrast microscopy image of uncrosslinked HA hydrogel-urea crystal composite; and
  • FIGURE 2F phase contrast microscopy image of crosslinked HA hydrogel after removal of the urea crystals;
  • FIGURES 3 A to 3 C are high magnification images of urea crystals and templated HA hydrogels;
  • FIGGURE 3B atomic force microscopy (AFM) image of the surface of a rinsed urea-templated HA hydrogel in air;
  • FIGURES 4A to 4C show the urea seed crystal technique used to control the morphology of crystals and pores within HA hydrogels;
  • FIGURE 4A three separate nucleation points producing a hydrogel with three radial patterns;
  • FIGGURE 4B line nucleation points producing a hydrogel with linear alignment of crystals;
  • FIGURE 4C magnified view of FIGURE 4B.
  • FIGURE 5A photograph of scaled-up free standing films of plain and urea- templated HA and alginate
  • FIGGURE 5B top down view of the scanning electron microscopy images (SEM) of crystal templated HA after cross-linking and rinsing
  • FIGGURE 5C portion of the film curled back to expose crevices in the hydrogel created by urea crystals
  • FIGURE 5D cross-section of the hydrogel perpendicular to the pore orientation
  • FIGURE 5E parallel cross-section depicting the fibrillar morphology
  • FIGURE 5F magnified view of image of FIGURE 5E; and
  • FIGURES 6A to 6F depict dendritic crystal growth within polymer solutions demonstrating many possible combinations of crystallizable molecules and polymers.
  • the crystals were imaged by polarized light (FIGURES 6A to 6E) and phase contrast microscopy (FIGURE 6F): (FIGURE 6A) urea crystal and alginate; (FIGURE 6B) urea crystal and 4-arm-PEG acrylate; (FIGURE 6C) urea crystal and chitosan; (FIGURE 6D) potassium phosphate crystal and hyaluronic acid; (FIGURE 6E) b-cyclodextrin crystal and alginate; and (FIGURE 6F) magnified image of b-cyclodextrin crystals and alginate. Scale bars are 1000 ⁇ m (FIGURES 6A to 6E) and 100 ⁇ m (FIGURE 6F).
  • Crystal- templating works by growing a dendritic crystal template within a solution of uncrosslinked biopolymer, crosslinking the biopolymer around the template, and removing the crystals by washing with water. The result is a macroporous hydrogel with a network of pores matching the shape of the crystal template.
  • the crystal- templating technique and the materials created by it address the challenge of fabricating materials with intricate dendritic micro-architecture that is observed in native tissues.
  • tissue engineering is to create materials that can replace or repair injured tissue.
  • tissue engineered constructs that mimic the microarchitecture of native tissues.
  • An important structural feature of many tissues is highly branched networks of vessels and ducts. Examples are the bronchioles, the microvasculature, lymphatic vessels, the ductal networks of salivary gland, mammary gland, and kidney, and the dendritic trees produced by neurons [1-4]. Such networks exhibit branching, multiple length scales, a directional orientation, and three- dimensionality.
  • a tissue may contain multiple entwined networks; for example, bronchioles, arterial vessels, and venous vessels within the lungs. Although many techniques are available for creating porosity within tissue engineered constructs they fall short of reproducing even one such network [5].
  • Rapid prototyping techniques permit precise control over pore morphology through the use of computer-aided design systems [11-13]. Rapid prototyping is suitable for creation of square and hexagonal lattices but not for the complex three-dimensional dendritic patterns observed in native tissues. Although rapid prototyping techniques are compatible with synthetic polymers they are not as suitable for natural materials which are water soluble and viscous. A further limitation is that the resolution of such techniques is larger than the length scale of individual cells and neuronal processes.
  • HA has found use as a dermal filler, adhesion barrier, intra-articular viscosupplement, vitreal substitute, drug delivery matrix and tissue engineering scaffold for cartilage, skin, adipose and vocal cord [15-21].
  • Alginate has been used extensively for cell encapsulation, drug delivery and tissue engineering of adipose and cartilage [22-24].
  • these polysaccharides are considerably more difficult to work with because they have high molecular weights, are polydisperse, organic insoluble, pH and temperature sensitive, and produce viscous solutions even at dilute concentrations.
  • it is a challenge to create tissue engineered scaffolds with biomimetic porous networks in HA and SA hydrogels.
  • the present invention describes a crystal-templating technique that uses in situ crystallization to carve out pores within biopolymer hydrogels.
  • Salts and small organic molecules can precipitate as crystalline branching networks under certain conditions.
  • the similarity between such networks and the dendritic patterns of microvasculature and neuronal dendritic trees prompted us to use in situ crystallization to template biopolymer hydrogels with macroporous networks.
  • SA and HA are both linear, unbranched, anionic, high molecular weight polysaccharides (their chemical structures are depicted in FIGURE. 1), however they are distinguished by their mode of crosslinking.
  • HA can be crosslinked by derivatization with methacrylate side chains and exposure to UV light and a photoinitiator [25].
  • Alginate can be crosslinked by addition of divalent cations which crosslink adjacent guluronic acid blocks [24]. Both modes of crosslinking are compatible with the crystal-templating technique of the present invention.
  • Urea was chosen as the crystallite because of its high water solubility and propensity for extensive hydrogen bonding to permit interaction with biopolymer chains in solution.
  • the method described in the present invention includes five steps: film casting, solvent evaporation, crystal growth, crosslinking, and rinsing. These steps are depicted in FIGURE 1. Small droplets ( ⁇ 2 ⁇ L) of biopolymer and urea were cast onto microscope slides.
  • the droplets were evaporated at -50% relative humidity to produce thin hydrated films of about 5 mm in diameter on microscope slides. Solvent evaporation is required to achieve the super-saturation conditions necessary for crystallization. Evaporation also greatly increases the biopolymer concentration and solution viscosity. The combination of high viscosity and hydrogen bonding suppresses spontaneous urea crystallization and facilitates super-saturation.
  • Urea seed crystals were deposited on the tips of a fine pair of tweezers and applied to the centers of each HA/urea and SA/urea film. Crystal growth began immediately and produced long dendritic branches that extended from the center to the edge of the film. Within seconds the entire volume of the hydrogel films were filled with urea crystals. These crystals comprised the urea crystal template.
  • FIGURE 1 shows the chemical structures of biopolymers used in these hydrogels and schematic of the crystal-templating technique.
  • Crystal templated hydrogels were created by casting solution of biopolymer and urea, e.g., hyaluronic acid and alginate. The solvent was evaporated to achieve supersaturation conditions concentrations of urea.
  • the biopolymer-urea droplet is added to the glass slide, followed by drying 2. Resulting in the application of a seed crystal to the center of the film nucleated crystallization as seen in 3. Following crystallization the biopolymer is crosslinked by either UV or calcium 4.
  • a water rinse 5 removes the urea crystals leaving behind a macroporous hydrogel templated 6 with the pattern of the urea crystals.
  • the films were crosslinked by either UV exposure or calcium as appropriate. Both methods of crosslinking are rapid and accurately preserve the configuration of the crystal template. After crosslinking the crystals were easily removed with water.
  • the end products were hydrogels with dendritic macroporous networks. Crystal-templated HA hydrogels are shown in FIGURE 2. These thin films are easily observable by transmission light microscopy. Droplets containing both biopolymer and urea crystals (i.e., biopolymer-urea "composites”) were highly birefringent when observed through crossed polarizers.
  • FIGURES 2A to 2F are polarized light (FIGURES 2A and 2D) and phase contrast (FIGURES 2B, 2C, 2E, and 2F) microscopy images of crystal templated HA hydrogel.
  • FIGURES 2A to 2D are images of the uncrosslinked hydrogel-crystal composite.
  • FIGURES 2E and 2F images of the hydrogels after crosslinking and removal of the urea crystals. Crystal growth was nucleated at the center of each hydrogel and grew radially outward toward the edge of the hydrogel.
  • the hydrogel-crystal composites in the first column exhibit a maltese cross characteristic of alignment.
  • the crystal template pattern was retained by the hydrogel after crosslinking and rinsing.
  • Scale bars are 1000 ⁇ m in FIGURES 2A to 2C and 100 ⁇ m in FIGURES 2D to 2F.
  • FIGURE 3 A depicts high magnification images of a growing urea crystal front.
  • FIGURES 3A to 3C are high magnification images of urea crystals and templated hyaluronic acid hydrogels.
  • FIGURE 3B is an AFM image of the surface of a rinsed urea-templated HA hydrogel in air. The ridges correspond to the HA hydrogel. The grooves between the ridges had contained urea crystals that were washed out. This image demonstrates that HA hydrogel was templated by the crystallization of urea.
  • FIGURE 3C shows a profile of the AFM image perpendicular to the orientation of the ridges.
  • the growth rate was highly dependent on the ratio of urea to HA concentrations. This ratio was adjusted by fixing the HA concentration at 10 mg/mL and varying the urea concentration from 2.5 to 180 mg/mL. Crystal growth could not be nucleated for a ratio of 0.25. For increasing ratios, the growth rate also increased and reached a rate of 1000 ⁇ m/sec for a ratio of 6. For ratios of 8 and greater a viscous liquid was expelled from the crystals shortly after crystallization. This liquid was easily visible under polarized light as dark liquid on the surface of the birefringent urea crystals. The liquid was likely rich in HA and photoinitiator which are impurities with respect to urea crystals.
  • FIG. 3B The micro-topography of a rinsed urea-templated HA hydrogel was observed by contact mode AFM in air (FIGURE 3B).
  • the surface of the hydrogel consisted of alternating parallel valleys and ridges. The valleys were carved out by the growth of urea crystals. During crystallization, the crystal front expels the biopolymer as an impurity. Thus, the biopolymer was compressed into the interstices between urea crystals and formed the radially aligned thin ridges.
  • FIGURE 3C A profile of the hydrogel perpendicular to the length of the ridges is shown in FIGURE 3C. The dimensions of these ridges, less than 1 ⁇ m in height and spaced between 1 and 2 ⁇ m apart, are consistent with our observations under the light microscope in FIGURE 3A.
  • Urea crystal growth can be nucleated two ways. Spontaneous nucleation occurs when the concentration of urea exceeds a critical super-saturation. Typically, spontaneous nucleation occurred on the edges of the hydrogels. Hydrogels never had more than one spontaneous nucleation event because crystal growth was very rapid.
  • FIGURES 4A to 4C show that the urea seed crystal technique can be used to control the morphology of crystals and pores within HA hydrogels.
  • FIGURE 4 A shows three separate nucleation points produced a hydrogel with three radial patterns.
  • FIGURE 4B shows a line of nucleation points produced a hydrogel with linear alignment of crystals.
  • FIGURE 4C shows a magnified image of FIGURE 4B. Scale bars are 1000 ⁇ m (FIGURE 4A and FIGURE 4B) and 100 ⁇ m (FIGURE 4C).
  • FIGURE 4A Application of three seeds produced the three domain template in FIGURE 4A. Individual seeds produced radial crystal growth, whereas a line of seeds produced parallel alignment throughout the hydrogel film (FIGURE 4B). Thus, seed nucleation is a simple method for engineering template morphology.
  • the droplets deposited on microscope slides formed thin films a few microns thick as estimated by electron microscopy.
  • Crosslinked films could be released from the surfaces of the microscope slides by agitation and transferred to solution for storage if desired. These films remained intact and did not fall apart, but could be enzymmatically degraded by hyaluronidase and dissolved by treatment with a calcium chelator, EDTA.
  • Scale-up of the urea-templating procedure was accomplished for both HA and SA using a procedure similar to that used for the droplets.
  • the scaled-up films were prepared by casting 2.6 mL of solution into 12-well plates with diameters of 2.2 cm per well. Three to four days were required to evaporate solvent. Crystal growth could be nucleated both spontaneously and by seed crystal.
  • FIGURES 5A to 5F shows the process of urea-templating was scaled up from droplets to thick films.
  • FIGURE 5A is a photograph of scaled-up freestanding films of plain and urea- templated HA and alginate.
  • FIGURES 5B to 5E are SEM images of crystal templated HA after crosslinking and rinsing.
  • FIGURE 5B is a top down view.
  • HA hydrogel was sculpted into a "fibrous" morphology.
  • FIGURE 5C this portion of the film was curled back to expose the crevices in the hydrogel that had been created by urea crystals.
  • FIGURE 5D shows a cross-section of the hydrogel perpendicular to the pore orientation depicting that the pores are present throughout the thickness of the hydrogel.
  • FIGURE 5E is a parallel cross-section depicting the fibrillar morphology.
  • FIGURE 5F is a magnified view of FIGURE 5E.
  • Crystal-templated films were opaque white and had a fibrillar morphology observable even by eye (FIGURE 5A).
  • non-templated films of HA were transparent and featureless.
  • Non-templated SA films were a light milky white and had a fine granular morphology when viewed under phase contrast microscopy. All templated and non- templated HA and SA films were durable, pliable and easy to handle in both dry and swollen conditions.
  • Scaled-up templated films were too thick for their features to be observed by optical microscopy; therefore, the morphology of these films was investigated by SEM. Dehydration of swollen hydrogel specimens can easily create artifacts in the hydrogel structure and particularly on the surface. To minimize such artifacts the SEM specimens were extensively soaked and rinsed with methanol rather than water to remove urea. Urea is highly soluble in methanol (-160 mg/mL) and the templated hydrogel swelled minimally. The urea crystals had been so tightly packed that the templated HA hydrogel had a fibrillar appearance.
  • FIGURE 5B When observed from the top-down a repeating "arrowhead" fibrillar morphology of the film was clearly revealed (FIGURE 5B). A curled portion of the film viewed at an angle revealed the interior crevices among the fibers that had contained the crystal template (FIGURE 5C). Cross-sections of the film perpendicular and parallel to the fiber orientation are depicted in FIGURES 5D and 5E, respectively. These cross-sections demonstrate that the pore and fiber morphology was present throughout the thickness of the film and not confined to the surfaces; thus, confirming that the templates are three-dimensional.
  • the crystal-templating technique is different from existing technology because the crystals are grown within the hydrogel. That is, crystallization begins at a point of nucleation and then radiates outwards filling the entire three dimensional volume. This process of growth ensures that the resulting pores are interconnected and oriented. Importantly, the crystals are suspended within the viscous biopolymer solution permitting crystal growth in three dimensions. Scale-up can be achieved because crystallization occurs rapidly over large distances. Crystallization of urea within HA and SA hydrogels was both easily reproducible and highly robust with respect to the concentrations of urea and biopolymer. This robustness to concentration permitted the hydrogels to be scaled from droplets to large films.
  • crystal templates were, however, sensitive to ambient humidity which affected the rate of solvent evaporation and the final water content of the evaporated, equilibrated hydrogel films. This sensitivity was circumvented through the use of controlled humidity conditions. Although crystal-templating lacks precise control over the final pore morphology this can be alleviated through temporal and spatial control of the nucleation event through the use of seed nucleation.
  • hyaluronic acid and alginate poly(ethylene glycol) acrylate hydrogels are also patternable by urea crystallization.
  • Exploration of other crystallites and crystal growth conditions will yield a range of template morphologies.
  • engineered potassium phosphate templates were determined that possess dendritic structures that are much larger and thicker than the urea templates.
  • Crystal engineering is a set of techniques that tailors the supramolecular assembly of crystalline materials by manipulating crystal growth conditions. Important parameters are the concentrations and ratios of biopolymer and urea, solution viscosity, pH, and temperature.
  • Additives such as surfactants and chiral molecules can selectively adhere to crystal faces and thereby control the branching, size and chirality of the resulting crystal structures [28]. Such techniques may be able to refine the crystal structures and to produce a wide selection of crystal templates.
  • the applications of crystal-templated hydrogels extend beyond tissue engineering because these hydrogels present a unique platform for the creation of composite materials. For example, infusion of the pores with cell adhesive proteins would be ideal for tissue engineering scaffolds. Polymerization reactions and biomineralization within the pores can yield novel composites in which one component is distributed throughout the other component in oriented dendritic micron-sized pores.
  • Photocrosslinkable HA was prepared by our standard procedure of derivatization of HA with glycidyl methacrylate to yield GMHA [25].
  • Urea-templated GMHA films were prepared as depicted in FIGURE IA.
  • An aqueous solution was prepared of 10 mg/mL
  • GMHA with 40 mg/mL urea and 0.5 mg/mL photoinitiator (Irgacure 2959) in distilled deionized water. Droplets of 2 ⁇ L were dispensed onto a glass microscope slide. The solvent was partially evaporated overnight at ambient conditions or in sealed containers with -50% relative humidity maintained by saturated solutions of calcium nitrate. GMHA is very hygroscopic and retained residual moisture in equilibrium with the humid atmosphere. Thus, evaporation yielded viscous hydrogel films that were super-saturated with urea. After drying, urea seed crystals were deposited onto the tips of a fine pair of tweezers by scraping the tweezers against solid urea.
  • tweezers were carefully touched to the center of each droplet to nucleate crystallization.
  • a razor-blade scraped against urea was used to nucleate straight lines.
  • GMHA was crosslinked by 1 minute of exposure to UV. The hydrogels were rinsed in water to remove urea.
  • Templated alginate hydrogels were prepared as shown in FIGURE IB. Aqueous solutions of 10 mg/mL alginate with 40 mg/mL urea were dispensed onto microscope slides and air- dried. After crystallization the hydrogels were crosslinked by covering the droplet 200 mg/niL calcium chloride solution for one minute. Rinsing with water removed excess calcium chloride and urea.
  • Templated PEG4A hydrogels were prepared from aqueous solutions of 60 mg/mL PEG4A, 40 mg/mL urea and 0.5 mg/mL Irgacure 2959.
  • Potassium phosphate templated GMHA was prepared from a solution of 20 mg/mL GMHA, 10 mg/mL potassium dihydrogen phosphate and 0.5 mg/mL Irgacure 2959. These droplets were incubated in humid chambers equilibrated with saturated sodium chloride solutions until crystal growth was complete.
  • Thick crystal-templated hydrogels were prepared under sterile conditions to prevent contamination during solvent evaporation.
  • Aqueous solutions were prepared as described above, filter sterilized (0.22 ⁇ m PVDF,
  • GMHA films were crosslinked by 1 minute of UV exposure, and rinsed extensively with exchanges of water over several days to remove urea. Alginate films were crosslinked by immersion in 200 mg/mL calcium chloride for twenty minutes and then rinsed extensively with water.
  • Plain GMHA films required an additional humidifying step after air-drying and before photocrosslinking. This step was required because the photocrosslinking reaction was moisture sensitive. It is likely necessary for water to be retained within the film to permit diffusion of photoinitiator and movement of GMHA chains during photoexposure. Therefore, air-dried films were placed in a sealed container at -85% relative humidity which was achieved by equilibration with saturated potassium chloride solution. GMHA films were incubated under these conditions for four days and then photocrosslinked by 1 minute of exposure to UV.
  • compositions of the invention can be used to achieve methods of the invention.
  • the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
  • the term “or combinations thereof as used herein refers to all permutations and combinations of the listed items preceding the term.
  • A, B, C, or combinations thereof is intended to include at least one of: A, B, C, AB, AC, BC, or ABC, and if order is important in a particular context, also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB.
  • expressly included are combinations that contain repeats of one or more item or term, such as BB, AAA, MB, BBC, AAABCCCC, CBBAAA, CABABB, and so forth.
  • BB BB
  • AAA AAA
  • MB BBC
  • AAABCCCCCC CBBAAA
  • CABABB CABABB
  • compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

Abstract

The present invention includes a hydrogel and a method of making a porous hydrogel by preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel; allowing the cast mixture to dry to form an amorphous hydrogel film; seeding the cast mixture with a seed crystal of the crystallizable molecule; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the polymer around the crystal structure under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel.

Description

DENDRITIC MACROPOROUS HYDROGELS PREPARED BY CRYSTAL
TEMPLATING
Technical Field of the Invention
The present invention relates in general to the field of hydrogels, and more particularly, to dendritic macroporous hydrogels prepared by crystal templating.
Background Art
Without limiting the scope of the invention, its background is described in connection with hydrogels. Hydrogels are generally polymer chain networks that are water-insoluble, but that absorb water. Often described as being "superabsorbent," hydrogels are able to retain up to 99% water and can be made from natural or synthetic polymers. Often, hydrogels will have a high degree of flexibility due to their high water content. Common uses for hydrogels include: sustained drug release, as scaffolds (e.g., in tissue engineering), as a thickening agent, as a biocompatible polymer, in biosensors and electrodes and for tissue replacement applications. Natural hydrogels may be made from agarose, methylcellulose, hyaluronic acid (HA), and other naturally-derived polymers.
One method for making hydrogels is a taught by United States Patent No. 7,307,132, issued to Nestler, et al, for a method of producing low-odor hydrogel-forming polymers. Briefly, a low-odor hydrogel-forming acrylic acid polymer is prepared by preparing a polymeric hydrogel by free-radically polymerizing a monomer composition comprising at least 50% by weight of acrylic acid in an aqueous polymerization medium and converting said hydrogel into a particulate hydrogel or into hydrogel-forming powder; and optionally treating the particulate hydrogel or said hydrogel-forming powder with a crosslinking substance which, actually or latently, contain at least two functional groups capable of reacting with the carboxyl groups on the addition polymer; characterized by the acrylic acid used in step (a) containing less than 400 ppm of acetic acid and propionic acid.
Another method is taught by United States Patent No. 6,943,206, issued to Haraguchi for an organic/inorganic hybrid hydrogel and method for manufacturing. Briefly, an organic/inorganic hybrid hydrogel is said to have superior homogeneity, transparency, mechanical properties, and swelling and shrinking properties. A dry body of the organic/inorganic hybrid hydrogel is obtained by removing water from said hydrogel. The organic/inorganic hybrid hydrogel comprises a water soluble polymer (A), a water swelling clay mineral (B) which can be homogeneously dispersed in water, and water (C), and water (C) is included in a three-dimensional network formed by (A) and (B).
Disclosure of the Invention
More particularly, the present invention includes a method of making a porous hydrogel by preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel; drying the cast mixture to form an amorphous hydrogel film; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the polymer around the crystal structure under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel. In one aspect, the method further includes seeding the cast mixture with a seed crystal, e.g., of the crystallizable molecule.
In one aspect, the polymer is nucleic acids, amino acids, saccharides, lipids and combinations thereof, in monomeric, dimeric, trimeric, oligomeric or polymeric forms. In another aspect, the polymer used in the method is selected from the group consisting of collagen, chitosan, gelatin, pectins, alginate, hyaluronic acid, heparin and mixtures thereof. In certain embodiments, the polymer is a biopolymer, which may be, e.g., natural, synthetic or even synthetic and natural. In one aspect, the polymer may be gelled by a chemical crosslink, a physical crosslink, or a combination. The crosslink is induced by UV, temperature, pH, an ion, or ion-radical based methods or combinations thereof. Non- limiting examples of crystallizable molecules include: a small organic molecule selected from urea, beta cyclodextrin, glycine and guanidine or a salt such as potassium dihydrogen phosphate. In one aspect, the method may further comprise adding a cross-linking agent to the mixture, the crosslinking agent selected from group consisting of p-Azidobenzoyl hydrazide, N-5-Azido-2-nitrobenzoyloxsuccinimide, disuccinimidyl glutamate, dimethyl pimelimidate-(2)HCl, dimethyl suberimidate-2 HCl, disuccinimidyl suberate, bis[sulfosuccinimidyl suberate], 1 -ethyl-3-[3-dimethylaminopropyl]carbodiimide-HCl, isocyanate, aldehyde, glutaraldehyde, paraformaldehyde and derivatives thereof. In certain aspects, the crystal structure forms a lattice structure and supports the polymer during the crosslinking step. In another aspect, the step of growing the crystal structure is by seeding the mixture with a crystal. In another aspect, the step of growing occurs by spontaneous crystal formation, e.g., during the step of drying the cast mixture.
In another embodiment, the present invention includes a porous hydrogel made by a method that includes preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel; drying the cast mixture to form an amorphous hydrogel film; seeding the cast mixture with a seed crystal of the crystallizable molecule; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the polymer around the crystal with a crosslinking agent under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel. In one aspect, the polymer is nucleic acids, amino acids, saccharides, lipids and combinations thereof, in monomeric, dimeric, trimeric, oligomeric or polymeric form. In another aspect, the polymer is selected from the group consisting of collagen, chitosan, gelatin, pectins, alginate, hyaluronic acid, heparin and mixtures thereof. In certain embodiments, the polymer is a biopolymer, which may be, e.g., natural, synthetic or even synthetic and natural. In one aspect, the polymer may be gelled by a chemical crosslink, a physical crosslink, or a combination. The crosslink is induced by UV, temperature, pH, an ion, or ion-radical based methods or combinations thereof. Non-limiting examples of crystallizable molecules include: a small organic molecule selected from urea, beta cyclodextrin, glycine and guanidine or a salt such as potassium dihydrogen phosphate. In one aspect, the method may further comprise adding a cross-linking agent to the mixture, the crosslinking agent selected from group consisting of p-Azidobenzoyl hydrazide, N-5- Azido-2-nitrobenzoyloxsuccinimide, disuccinimidyl glutamate, dimethyl pimelimidate- (2)HC1, dimethyl suberimidate-2 HCl, disuccinimidyl suberate, bis[sulfosuccinimidyl suberate], l-ethyl-3-[3-dimethylaminopropyl]carbodiimide-HCl, isocyanate, aldehyde, glutaraldehyde, paraformaldehyde and derivatives thereof. In certain aspects, the crystal structure forms a lattice structure and supports the polymer during the crosslinking step. In another aspect, the step of growing the crystal structure is by seeding the mixture with a crystal. Another embodiment of the present invention is a hydrogel that includes molecular pores, the hydrogel having one or more crosslinked polymers formed about a plurality of preformed molecular crystals, wherein the crystals are formed while the polymer is in uncrosslinked form and the molecular crystals form a porous structure within the polymers during crosslinking of the polymers.
Description of the Drawings
For a more complete understanding of the features and advantages of the present invention, reference is now made to the detailed description of the invention along with the accompanying figures and in which:
FIGURE 1 shows the chemical structures of biopolymers used in these hydrogels and a schematic of the crystal-templating technique;
FIGURES 2A to 2F are polarized light (FIGURES 2A and 2D) and phase contrast (FIGURES 2B, 2C, 2E, and 2F) microscopy images of crystal templated HA hydrogel; (FIGURE 2A) polarized light microscopy image of uncrosslinked HA hydrogel-urea crystal composite; (FIGURE 2B) phase contrast microscopy image of uncrosslinked HA hydrogel-urea crystal composite; (FIGURE 2C) phase contrast microscopy image of crosslinked HA hydrogel after removal of the urea crystals; (FIGURE 2D) polarized light microscopy image of uncrosslinked HA hydrogel-urea crystal composite; (FIGURE 2E) phase contrast microscopy image of uncrosslinked HA hydrogel-urea crystal composite; and (FIGURE 2F) phase contrast microscopy image of crosslinked HA hydrogel after removal of the urea crystals;
FIGURES 3 A to 3 C are high magnification images of urea crystals and templated HA hydrogels; (FIGURE 3A) time lapse series of the urea crystal front captures with video Brightfield microscopy; (FIGURE 3B) atomic force microscopy (AFM) image of the surface of a rinsed urea-templated HA hydrogel in air; and (FIGURE 3C) profile of the AFM image perpendicular to the orientation of the ridges;
FIGURES 4A to 4C show the urea seed crystal technique used to control the morphology of crystals and pores within HA hydrogels; (FIGURE 4A) three separate nucleation points producing a hydrogel with three radial patterns; (FIGURE 4B) line nucleation points producing a hydrogel with linear alignment of crystals; and (FIGURE 4C) magnified view of FIGURE 4B. Scale bars are 1000 μm (FIGURES 4A and 4B) and 100 μm (FIGURE FIGURES 5 A to 5F shows the process of urea-templating scaled up from droplets to thick films; (FIGURE 5A) photograph of scaled-up free standing films of plain and urea- templated HA and alginate; (FIGURE 5B) top down view of the scanning electron microscopy images (SEM) of crystal templated HA after cross-linking and rinsing; (FIGURE 5C) portion of the film curled back to expose crevices in the hydrogel created by urea crystals; (FIGURE 5D) cross-section of the hydrogel perpendicular to the pore orientation; (FIGURE 5E) parallel cross-section depicting the fibrillar morphology; and (FIGURE 5F) magnified view of image of FIGURE 5E; and
FIGURES 6A to 6F depict dendritic crystal growth within polymer solutions demonstrating many possible combinations of crystallizable molecules and polymers. The crystals were imaged by polarized light (FIGURES 6A to 6E) and phase contrast microscopy (FIGURE 6F): (FIGURE 6A) urea crystal and alginate; (FIGURE 6B) urea crystal and 4-arm-PEG acrylate; (FIGURE 6C) urea crystal and chitosan; (FIGURE 6D) potassium phosphate crystal and hyaluronic acid; (FIGURE 6E) b-cyclodextrin crystal and alginate; and (FIGURE 6F) magnified image of b-cyclodextrin crystals and alginate. Scale bars are 1000 μm (FIGURES 6A to 6E) and 100 μm (FIGURE 6F).
Description of the Invention
While the making and using of various embodiments of the present invention are discussed in detail below, it should be appreciated that the present invention provides many applicable inventive concepts that can be embodied in a wide variety of specific contexts. The specific embodiments discussed herein are merely illustrative of specific ways to make and use the invention and do not delimit the scope of the invention.
To facilitate the understanding of this invention, a number of terms are defined below. Terms defined herein have meanings as commonly understood by a person of ordinary skill in the areas relevant to the present invention. Terms such as "a", "an" and "the" are not intended to refer to only a singular entity, but include the general class of which a specific example may be used for illustration. The terminology herein is used to describe specific embodiments of the invention, but their usage does not delimit the invention, except as outlined in the claims. The creation of macroporosity within tissue engineering scaffolds is important because it influences cellular infiltration, scaffold remodeling, nutrient diffusion, vascular in-growth and functional integration with native tissues. The present inventors have developed a novel crystal-templating technique to fabricate hydrogels with continuous dendritic porous networks. No other current method is capable of creating such scaffolds. Additional advantages of this technique are that it is compatible with natural biomaterials, it is fast, can be scaled up, and does not require any expensive equipment or reagents. Crystal- templating works by growing a dendritic crystal template within a solution of uncrosslinked biopolymer, crosslinking the biopolymer around the template, and removing the crystals by washing with water. The result is a macroporous hydrogel with a network of pores matching the shape of the crystal template. We have used urea crystal templates to pattern photocrosslinked HA and calcium-crosslinked alginate hydrogels. The crystal- templating technique and the materials created by it address the challenge of fabricating materials with intricate dendritic micro-architecture that is observed in native tissues.
The goal of tissue engineering is to create materials that can replace or repair injured tissue. To that end it is desirable to have tissue engineered constructs that mimic the microarchitecture of native tissues. An important structural feature of many tissues is highly branched networks of vessels and ducts. Examples are the bronchioles, the microvasculature, lymphatic vessels, the ductal networks of salivary gland, mammary gland, and kidney, and the dendritic trees produced by neurons [1-4]. Such networks exhibit branching, multiple length scales, a directional orientation, and three- dimensionality. A tissue may contain multiple entwined networks; for example, bronchioles, arterial vessels, and venous vessels within the lungs. Although many techniques are available for creating porosity within tissue engineered constructs they fall short of reproducing even one such network [5].
Briefly, current techniques available for creating porosity are gas-foaming, lyophilization, thermally-induced phase separation and porogen leaching of salts and un-crosslinked polymer microspheres [6-8]. Soft replica molding can transfer patterns from etched silicon to polymers such as poly(lactide-co-glycolide), however this is a two-dimensional technique and the stacked layers are a poor approximation of three-dimensional porosity
[9-10]. The advantages of these methods are that they are easy to implement and scale-up. The disadvantage is that they provide little control over pore morphology and limited compatibility with natural materials. Rapid prototyping techniques permit precise control over pore morphology through the use of computer-aided design systems [11-13]. Rapid prototyping is suitable for creation of square and hexagonal lattices but not for the complex three-dimensional dendritic patterns observed in native tissues. Although rapid prototyping techniques are compatible with synthetic polymers they are not as suitable for natural materials which are water soluble and viscous. A further limitation is that the resolution of such techniques is larger than the length scale of individual cells and neuronal processes. Scaffolds depicted in the literature typically have features hundreds of microns in length which are too large to precisely guide cellular infiltration. Fabrication of three-dimensional multilayer constructs can be impractical because each scaffold must be built layer by layer with costly equipment. Hydrogel scaffolds are uniquely suited for tissue engineering applications because they more closely resemble natural tissues with respect to mechanical properties, porosity, and water content than do other materials [14]. In particular, polysaccharides, such as hyaluronic acid (HA) and sodium alginate (SA) are attractive materials because they are composed of the same chemical constituents as native extracellular matrix components. They also exhibit excellent biocompatibility and non-immunogenicity. HA has found use as a dermal filler, adhesion barrier, intra-articular viscosupplement, vitreal substitute, drug delivery matrix and tissue engineering scaffold for cartilage, skin, adipose and vocal cord [15-21]. Alginate has been used extensively for cell encapsulation, drug delivery and tissue engineering of adipose and cartilage [22-24]. In comparison to synthetic materials, these polysaccharides are considerably more difficult to work with because they have high molecular weights, are polydisperse, organic insoluble, pH and temperature sensitive, and produce viscous solutions even at dilute concentrations. Thus, it is a challenge to create tissue engineered scaffolds with biomimetic porous networks in HA and SA hydrogels. To address this problem the present invention describes a crystal-templating technique that uses in situ crystallization to carve out pores within biopolymer hydrogels. Salts and small organic molecules can precipitate as crystalline branching networks under certain conditions. The similarity between such networks and the dendritic patterns of microvasculature and neuronal dendritic trees prompted us to use in situ crystallization to template biopolymer hydrogels with macroporous networks. SA and HA are both linear, unbranched, anionic, high molecular weight polysaccharides (their chemical structures are depicted in FIGURE. 1), however they are distinguished by their mode of crosslinking. HA can be crosslinked by derivatization with methacrylate side chains and exposure to UV light and a photoinitiator [25]. Alginate can be crosslinked by addition of divalent cations which crosslink adjacent guluronic acid blocks [24]. Both modes of crosslinking are compatible with the crystal-templating technique of the present invention. Urea was chosen as the crystallite because of its high water solubility and propensity for extensive hydrogen bonding to permit interaction with biopolymer chains in solution. The method described in the present invention includes five steps: film casting, solvent evaporation, crystal growth, crosslinking, and rinsing. These steps are depicted in FIGURE 1. Small droplets (~2 μL) of biopolymer and urea were cast onto microscope slides. The droplets were evaporated at -50% relative humidity to produce thin hydrated films of about 5 mm in diameter on microscope slides. Solvent evaporation is required to achieve the super-saturation conditions necessary for crystallization. Evaporation also greatly increases the biopolymer concentration and solution viscosity. The combination of high viscosity and hydrogen bonding suppresses spontaneous urea crystallization and facilitates super-saturation. Urea seed crystals were deposited on the tips of a fine pair of tweezers and applied to the centers of each HA/urea and SA/urea film. Crystal growth began immediately and produced long dendritic branches that extended from the center to the edge of the film. Within seconds the entire volume of the hydrogel films were filled with urea crystals. These crystals comprised the urea crystal template.
FIGURE 1 shows the chemical structures of biopolymers used in these hydrogels and schematic of the crystal-templating technique. Crystal templated hydrogels were created by casting solution of biopolymer and urea, e.g., hyaluronic acid and alginate. The solvent was evaporated to achieve supersaturation conditions concentrations of urea. As seen in 1 the biopolymer-urea droplet is added to the glass slide, followed by drying 2. Resulting in the application of a seed crystal to the center of the film nucleated crystallization as seen in 3. Following crystallization the biopolymer is crosslinked by either UV or calcium 4. A water rinse 5 removes the urea crystals leaving behind a macroporous hydrogel templated 6 with the pattern of the urea crystals. After the completion of the crystallization the films were crosslinked by either UV exposure or calcium as appropriate. Both methods of crosslinking are rapid and accurately preserve the configuration of the crystal template. After crosslinking the crystals were easily removed with water. The end products were hydrogels with dendritic macroporous networks. Crystal-templated HA hydrogels are shown in FIGURE 2. These thin films are easily observable by transmission light microscopy. Droplets containing both biopolymer and urea crystals (i.e., biopolymer-urea "composites") were highly birefringent when observed through crossed polarizers. These composite films exhibited a characteristic maltese cross pattern indicative of radial alignment. The colors of the composites in polarized light appeared to correspond to film thickness; the films were thickest at the center and thinned out toward the edges. After crosslinking and rinsing, the hydrogels lost most of their birefringence and exhibited only a faint white color when viewed through crossed polarizers. The hydrogel morphology consisted of aligned straight "fibrils" that were the inverse shape of the crystal template. FIGURES 2A to 2F are polarized light (FIGURES 2A and 2D) and phase contrast (FIGURES 2B, 2C, 2E, and 2F) microscopy images of crystal templated HA hydrogel. FIGURES 2A to 2D are images of the uncrosslinked hydrogel-crystal composite. FIGURES 2E and 2F images of the hydrogels after crosslinking and removal of the urea crystals. Crystal growth was nucleated at the center of each hydrogel and grew radially outward toward the edge of the hydrogel. The hydrogel-crystal composites in the first column exhibit a maltese cross characteristic of alignment. The crystal template pattern was retained by the hydrogel after crosslinking and rinsing. Scale bars are 1000 μm in FIGURES 2A to 2C and 100 μm in FIGURES 2D to 2F.
Images of urea crystal growth were captured using video microscopy. FIGURE 3 A depicts high magnification images of a growing urea crystal front. FIGURES 3A to 3C are high magnification images of urea crystals and templated hyaluronic acid hydrogels. FIGURE
3A is a time lapse series of the urea crystal front captured with video Brightfield microscopy. Images are five seconds apart. Scale bar = 10 μm. FIGURE 3B is an AFM image of the surface of a rinsed urea-templated HA hydrogel in air. The ridges correspond to the HA hydrogel. The grooves between the ridges had contained urea crystals that were washed out. This image demonstrates that HA hydrogel was templated by the crystallization of urea. FIGURE 3C shows a profile of the AFM image perpendicular to the orientation of the ridges.
It was found that the crystals were thin tightly packed needles that sprouted a high density of branches. As the urea branches approached neighboring crystals the local concentration of urea became depleted and branch growth was terminated; therefore, the longest continuous branches were those that grew in the most radial direction away from the point of nucleation. Direct observation of crystal growth confirmed that the crystals grew continuously; therefore, we conclude that the porous network within the crystal-templated hydrogels is also continuous. Branches were not observed when urea crystals were grown in the absence of biopolymer which indicates the importance of viscosity to induction of dendritic growth. Such an effect has been observed by others that have examined crystal growth in the presence of polymers [26, 27]. We found that the growth rate was highly dependent on the ratio of urea to HA concentrations. This ratio was adjusted by fixing the HA concentration at 10 mg/mL and varying the urea concentration from 2.5 to 180 mg/mL. Crystal growth could not be nucleated for a ratio of 0.25. For increasing ratios, the growth rate also increased and reached a rate of 1000 μm/sec for a ratio of 6. For ratios of 8 and greater a viscous liquid was expelled from the crystals shortly after crystallization. This liquid was easily visible under polarized light as dark liquid on the surface of the birefringent urea crystals. The liquid was likely rich in HA and photoinitiator which are impurities with respect to urea crystals. At higher ratios the urea crystals became increasingly more tightly packed and less branched. Bulk polyhedral urea crystals were observed on the surface of the needle crystals when the ratio was 18. We concluded that ratios of 6 and under were most effective at templating the biopolymer because this ensured that the hydrogel was templated by the crystals rather than excluded from the template.
The micro-topography of a rinsed urea-templated HA hydrogel was observed by contact mode AFM in air (FIGURE 3B). The surface of the hydrogel consisted of alternating parallel valleys and ridges. The valleys were carved out by the growth of urea crystals. During crystallization, the crystal front expels the biopolymer as an impurity. Thus, the biopolymer was compressed into the interstices between urea crystals and formed the radially aligned thin ridges. A profile of the hydrogel perpendicular to the length of the ridges is shown in FIGURE 3C. The dimensions of these ridges, less than 1 μm in height and spaced between 1 and 2 μm apart, are consistent with our observations under the light microscope in FIGURE 3A.
Urea crystal growth can be nucleated two ways. Spontaneous nucleation occurs when the concentration of urea exceeds a critical super-saturation. Typically, spontaneous nucleation occurred on the edges of the hydrogels. Hydrogels never had more than one spontaneous nucleation event because crystal growth was very rapid.
FIGURES 4A to 4C show that the urea seed crystal technique can be used to control the morphology of crystals and pores within HA hydrogels. FIGURE 4 A shows three separate nucleation points produced a hydrogel with three radial patterns. FIGURE 4B shows a line of nucleation points produced a hydrogel with linear alignment of crystals. FIGURE 4C shows a magnified image of FIGURE 4B. Scale bars are 1000 μm (FIGURE 4A and FIGURE 4B) and 100 μm (FIGURE 4C).
Applying a seed crystal to initiate urea crystal growth was a simple method for controlling the macro-morphology structure of the crystal template. This was done in conditions that suppressed spontaneous nucleation by partially drying the hydrogel droplets under humid conditions. At equilibrium under humid conditions the hydrated films have a concentration of urea great enough to sustain crystal growth but too low for spontaneous nucleation. Un- nucleated hydrogel films could be maintained for days until the introduction of a seed crystal. This permits selection of both the time and location of the nucleation. Films produced by the application of one seed in the center of the film are depicted in FIGURE 2.
Application of three seeds produced the three domain template in FIGURE 4A. Individual seeds produced radial crystal growth, whereas a line of seeds produced parallel alignment throughout the hydrogel film (FIGURE 4B). Thus, seed nucleation is a simple method for engineering template morphology.
The droplets deposited on microscope slides formed thin films a few microns thick as estimated by electron microscopy. Crosslinked films could be released from the surfaces of the microscope slides by agitation and transferred to solution for storage if desired. These films remained intact and did not fall apart, but could be enzymmatically degraded by hyaluronidase and dissolved by treatment with a calcium chelator, EDTA. Scale-up of the urea-templating procedure was accomplished for both HA and SA using a procedure similar to that used for the droplets. The scaled-up films were prepared by casting 2.6 mL of solution into 12-well plates with diameters of 2.2 cm per well. Three to four days were required to evaporate solvent. Crystal growth could be nucleated both spontaneously and by seed crystal.
FIGURES 5A to 5F shows the process of urea-templating was scaled up from droplets to thick films. FIGURE 5A is a photograph of scaled-up freestanding films of plain and urea- templated HA and alginate. FIGURES 5B to 5E are SEM images of crystal templated HA after crosslinking and rinsing. FIGURE 5B is a top down view. HA hydrogel was sculpted into a "fibrous" morphology. In FIGURE 5C, this portion of the film was curled back to expose the crevices in the hydrogel that had been created by urea crystals. FIGURE 5D shows a cross-section of the hydrogel perpendicular to the pore orientation depicting that the pores are present throughout the thickness of the hydrogel. FIGURE 5E is a parallel cross-section depicting the fibrillar morphology. FIGURE 5F is a magnified view of FIGURE 5E.
Crystal-templated films were opaque white and had a fibrillar morphology observable even by eye (FIGURE 5A). In contrast, non-templated films of HA were transparent and featureless. Non-templated SA films were a light milky white and had a fine granular morphology when viewed under phase contrast microscopy. All templated and non- templated HA and SA films were durable, pliable and easy to handle in both dry and swollen conditions.
Scaled-up templated films were too thick for their features to be observed by optical microscopy; therefore, the morphology of these films was investigated by SEM. Dehydration of swollen hydrogel specimens can easily create artifacts in the hydrogel structure and particularly on the surface. To minimize such artifacts the SEM specimens were extensively soaked and rinsed with methanol rather than water to remove urea. Urea is highly soluble in methanol (-160 mg/mL) and the templated hydrogel swelled minimally. The urea crystals had been so tightly packed that the templated HA hydrogel had a fibrillar appearance. When observed from the top-down a repeating "arrowhead" fibrillar morphology of the film was clearly revealed (FIGURE 5B). A curled portion of the film viewed at an angle revealed the interior crevices among the fibers that had contained the crystal template (FIGURE 5C). Cross-sections of the film perpendicular and parallel to the fiber orientation are depicted in FIGURES 5D and 5E, respectively. These cross-sections demonstrate that the pore and fiber morphology was present throughout the thickness of the film and not confined to the surfaces; thus, confirming that the templates are three-dimensional.
The crystal-templating technique is different from existing technology because the crystals are grown within the hydrogel. That is, crystallization begins at a point of nucleation and then radiates outwards filling the entire three dimensional volume. This process of growth ensures that the resulting pores are interconnected and oriented. Importantly, the crystals are suspended within the viscous biopolymer solution permitting crystal growth in three dimensions. Scale-up can be achieved because crystallization occurs rapidly over large distances. Crystallization of urea within HA and SA hydrogels was both easily reproducible and highly robust with respect to the concentrations of urea and biopolymer. This robustness to concentration permitted the hydrogels to be scaled from droplets to large films. The formation of the crystal templates was, however, sensitive to ambient humidity which affected the rate of solvent evaporation and the final water content of the evaporated, equilibrated hydrogel films. This sensitivity was circumvented through the use of controlled humidity conditions. Although crystal-templating lacks precise control over the final pore morphology this can be alleviated through temporal and spatial control of the nucleation event through the use of seed nucleation.
In addition to hyaluronic acid and alginate poly(ethylene glycol) acrylate hydrogels are also patternable by urea crystallization.. Exploration of other crystallites and crystal growth conditions will yield a range of template morphologies. For example, engineered potassium phosphate templates were determined that possess dendritic structures that are much larger and thicker than the urea templates. Crystal engineering is a set of techniques that tailors the supramolecular assembly of crystalline materials by manipulating crystal growth conditions. Important parameters are the concentrations and ratios of biopolymer and urea, solution viscosity, pH, and temperature. Additives such as surfactants and chiral molecules can selectively adhere to crystal faces and thereby control the branching, size and chirality of the resulting crystal structures [28]. Such techniques may be able to refine the crystal structures and to produce a wide selection of crystal templates. The applications of crystal-templated hydrogels extend beyond tissue engineering because these hydrogels present a unique platform for the creation of composite materials. For example, infusion of the pores with cell adhesive proteins would be ideal for tissue engineering scaffolds. Polymerization reactions and biomineralization within the pores can yield novel composites in which one component is distributed throughout the other component in oriented dendritic micron-sized pores.
Sodium hyaluronate from Streptococcus equi of molecular weight 1.6x106 Da as indicated by supplier and low viscosity alginic acid from brown algae were obtained from Sigma- Aldrich (St. Louis, MO). Tetra- functional poly(ethylene glycol) acrylate (PEG4A, MW = 10 kDa) was obtained from SunBio. Photoinitiator, Irgacure 2959, was obtained from Ciba Specialty Chemicals (Basel, Switzerland). Photopolymerizations were initiated by a longwave UV lamp filtered around 365 nm and with an intensity of 22 mW/cm2 (Blak-Ray B-100A, UVP, Upland, CA).
Photocrosslinkable HA was prepared by our standard procedure of derivatization of HA with glycidyl methacrylate to yield GMHA [25]. Urea-templated GMHA films were prepared as depicted in FIGURE IA. An aqueous solution was prepared of 10 mg/mL
GMHA with 40 mg/mL urea and 0.5 mg/mL photoinitiator (Irgacure 2959) in distilled deionized water. Droplets of 2 μL were dispensed onto a glass microscope slide. The solvent was partially evaporated overnight at ambient conditions or in sealed containers with -50% relative humidity maintained by saturated solutions of calcium nitrate. GMHA is very hygroscopic and retained residual moisture in equilibrium with the humid atmosphere. Thus, evaporation yielded viscous hydrogel films that were super-saturated with urea. After drying, urea seed crystals were deposited onto the tips of a fine pair of tweezers by scraping the tweezers against solid urea. Then the tweezers were carefully touched to the center of each droplet to nucleate crystallization. Similarly, a razor-blade scraped against urea was used to nucleate straight lines. GMHA was crosslinked by 1 minute of exposure to UV. The hydrogels were rinsed in water to remove urea.
Templated alginate hydrogels were prepared as shown in FIGURE IB. Aqueous solutions of 10 mg/mL alginate with 40 mg/mL urea were dispensed onto microscope slides and air- dried. After crystallization the hydrogels were crosslinked by covering the droplet 200 mg/niL calcium chloride solution for one minute. Rinsing with water removed excess calcium chloride and urea.
Templated PEG4A hydrogels were prepared from aqueous solutions of 60 mg/mL PEG4A, 40 mg/mL urea and 0.5 mg/mL Irgacure 2959. Potassium phosphate templated GMHA was prepared from a solution of 20 mg/mL GMHA, 10 mg/mL potassium dihydrogen phosphate and 0.5 mg/mL Irgacure 2959. These droplets were incubated in humid chambers equilibrated with saturated sodium chloride solutions until crystal growth was complete.
Scale-up of Crystal Templated Hydrogels. Thick crystal-templated hydrogels were prepared under sterile conditions to prevent contamination during solvent evaporation.
Aqueous solutions were prepared as described above, filter sterilized (0.22 μm PVDF,
Millipore), and dispensed into sterile, non-tissue culture treated 12-well plates. Each well was 2.2 cm in diameter and a volume of 2.6 mL of sterile solution was dispensed per well.
The solvent was evaporated in a sterile horizontal flow hood in the dark for four days. During this time urea crystallization either nucleated spontaneously or was nucleated by the seed crystal technique. Once nucleated, crystallization is rapid and therefore spontaneously nucleated films had only one nucleation point. GMHA films were crosslinked by 1 minute of UV exposure, and rinsed extensively with exchanges of water over several days to remove urea. Alginate films were crosslinked by immersion in 200 mg/mL calcium chloride for twenty minutes and then rinsed extensively with water.
Plain GMHA films required an additional humidifying step after air-drying and before photocrosslinking. This step was required because the photocrosslinking reaction was moisture sensitive. It is likely necessary for water to be retained within the film to permit diffusion of photoinitiator and movement of GMHA chains during photoexposure. Therefore, air-dried films were placed in a sealed container at -85% relative humidity which was achieved by equilibration with saturated potassium chloride solution. GMHA films were incubated under these conditions for four days and then photocrosslinked by 1 minute of exposure to UV.
It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method, kit, reagent, or composition of the invention, and vice versa. Furthermore, compositions of the invention can be used to achieve methods of the invention.
It will be understood that particular embodiments described herein are shown by way of illustration and not as limitations of the invention. The principal features of this invention can be employed in various embodiments without departing from the scope of the invention. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the claims. All publications and patent applications mentioned in the specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The use of the word "a" or "an" when used in conjunction with the term "comprising" in the claims and/or the specification may mean "one," but it is also consistent with the meaning of "one or more," "at least one," and "one or more than one." The use of the term "or" in the claims is used to mean "and/or" unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and "and/or." Throughout this application, the term "about" is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects.
[0100] As used in this specification and claim(s), the words "comprising" (and any form of comprising, such as "comprise" and "comprises"), "having" (and any form of having, such as "have" and "has"), "including" (and any form of including, such as "includes" and "include") or "containing" (and any form of containing, such as "contains" and "contain") are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. The term "or combinations thereof as used herein refers to all permutations and combinations of the listed items preceding the term. For example, "A, B, C, or combinations thereof is intended to include at least one of: A, B, C, AB, AC, BC, or ABC, and if order is important in a particular context, also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB. Continuing with this example, expressly included are combinations that contain repeats of one or more item or term, such as BB, AAA, MB, BBC, AAABCCCC, CBBAAA, CABABB, and so forth. The skilled artisan will understand that typically there is no limit on the number of items or terms in any combination, unless otherwise apparent from the context.
All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
REFERENCES
United States Patent No. 7,307,132. United States Patent No. 6,943,206. 1) Larina, O. & Thorn, P. Ca2+ dynamics in salivary acinar cells: distinct morphology of the acinar lumen underlies near-synchronous global Ca2+ responses. J. Cell ScL 118, 4131-4139 (2005).
2) Brisken, C. & Rajaram, R.D. Alveolar and lactogenic differentiation. J. Mammary Gland Biol. Neoplasia 11, 239-248 (2006). 3) Shah, M.M., Sampogna, R.V., Sakurai, H., Bush, K.T., Nigam, S.K. Branching morphogenesis and kidney disease. Development 131, 1449-1462 (2004).
4) Bekkers, J.M. & Hausser, M. Targeted dendrotomy reveals active and passive contributions of the dendritic tree to synaptic integration and neuronal output. P. Natl. Acad. Sci. USA 104, 11447-11452 (2007). 5) Khademhosseini, A., Langer, R., Borenstein, J., Vacanti, J.P. Microscale technologies for tissue engineering and biology. P. Natl. Acad. Sci. USA 103, 2480-2487 (2006).
6) Mikos, A.G., Thorsen, A.J., Czerwonka, L.A., Bao, Y., Langer, R., Winslow, D.N., Vacanti, J.P. Preparation and characterization of poly(L-lactic acid) foams. Polymer 35,
1068-1077 (1994).
7) Ma, P.X. & Choi, J.W. Biodegradable polymer scaffolds with well-defined interconnected spherical pore network. Tissue Eng. 7, 23-33 (2001).
8) Chen, J., Park, H., Park, K. Synthesis of superporous hydrogels: hydrogels with fast swelling and superabsorbent properties. J. Biomed. Mater. Res. 44, 53-62 (1999).
9) King, K.R., Wang, C.C.J., Kaazempur-Mofrad, M.R., Vacanti, J.P., Borenstein, J.T. Biodegradable microfluidics. Adv. Mater. 16, 2007-2012 (2004).
10) Duffy, D.C., McDonald, J.C., Schueller, O.J.A., Whitesides, G.M. Rapid prototyping of micro fluidic systems in poly(dimethylsiloxane). Anal. Chem. 70, 4974-4984 (1998).
11) Yang, S. F., Leong, K.F., Du, Z., Chua, CK. The design of scaffolds for use in tissue engineering. Part II. Rapid prototyping techniques. Tissue Eng. 8, 1-11 (2002).
12) Lu, Y., Mapili, G., Suhali, G., Chen, S., Roy, K. A digital micro-mirror device- based system for the microfabrication of complex, spatially patterned tissue engineering scaffolds. J. Biomed. Mater. Res. 77A, 396-405 (2006).
13) Tsang, V. L. et al. Fabrication of 3D hepatic tissue by additive photopatterning of cellular hydrogels. FASEB J. 21, 790-801 (2007).
14) Peppas, N.A., Bures, P., Leobandung, W., Ichikawa, H. Hydrogels in pharmaceutical formulations. Eur. J. Pharm. Biopharm. 50, 27-46 (2000). 15) Marshall, K. W. Intra-articular hyaluronan therapy. Curr. Opin. Rheumatol. 12, 468- 474 (2000).
16) Reijnen, M.M.P.J., Bleichrodt, R.P., van Goor, H. Pathophysiology of intraabdominal adhesion and abscess formation, and the effect of hyaluronan. Brit. J. Surg. 90, 533-541 (2003). 17) Monheit, G.D. & Coleman, K.M. Hyaluronic acid fillers. Dermatol. Ther. 19, 141- 150 (2006).
18) Chung, C. et al. Effects of auricular chondrocyte expansion on neocartilage formation in photocrosslinked hyaluronic acid networks. Tissue Eng. 12, 2665-2673 (2006).
19) Park, S.N., Kim, J.K., Suh, H. Evaluation of antibiotic-loaded collagen-hyaluronic acid matrix as a skin substitute. Biomaterials 25, 3689-3698 (2004).
20) Jia, X. Q. et al. Synthesis and characterization of in situ cross-linkable hyaluronic acid-based hydrogels with potential application for vocal fold regeneration. Macromolecules 37, 3239-3248 (2004).
21) Hemmrich, K. et al. Implantation of preadipocyte-loaded hyaluronic acid-based scaffolds into nude mice to evaluate potential for soft tissue engineering. Biomaterials 26, 7025-7037 (2005).
22) Uludag, H., de Vos, P., Trasco, P.A. Technology of mammalian cell encapsulation. Adv. Drug Deliver. Rev. 42, 29-64 (2000).
23) George, M. & Abraham, T.E. Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan - a review. J. Control. Release 114, 1-14 (2006).
24) Augst, A.D., Kong, H. J., Mooney, D.J. Alginate hydrogels as biomaterials. Macromol. Biosci. 6, 623-633 (2006). 25) Leach, J.B., Bivens, K.A., Patrick, C.W., Schmidt, CE. Photocrosslinked hyaluronic acid hydrogels: natural, biodegradable tissue engineering scaffolds. Biotechnol. Bioeng. 82, 578-589 (2003).
26) Oaki, Y. & Imai, H. Experimental demonstration for the morphological evolution of crystals grown in gel media. Cryst. Growth Des. 3, 711-716 (2003). 27) Ulcinas, A., Butler, M.F., Heppenstall-Butler, M., Singleton, S., Miles, M.J. Direct observation of spherulitic growth stages of CaCO3 in a poly(acrylic acid)-chitosan system: In situ SPM study. J. Cryst. Growth 307, 378-85 (2007).
28) Xu, A., Ma, Y., Colfen, H. Biomimetic mineralization. J. Mater. Chem. 17, 415- 449 (2007).

Claims

What is claimed is:
1. A method of making a porous hydrogel comprising: preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel to form a cast mixture; drying the cast mixture to form an amorphous hydrogel film; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the uncrosslinked polymer around the crystal structure under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel.
2. The method of claim 1, wherein the polymer comprises nucleic acids, amino acids, saccharides, lipids and combinations thereof, in monomeric, dimeric, trimeric, oligomeric, multimeric, or polymeric forms.
3. The method of claim 1, wherein the polymer is selected from the group consisting of collagen, chitosan, gelatin, pectins, alginate, hyaluronic acid, heparin and mixtures thereof.
4. The method of claim 1 , wherein the polymer comprises a biopolymer.
5. The method of claim 1 , wherein the polymer is a synthetic polymer.
6. The method of claim 1, wherein the polymer is gelled by a chemical crosslink, a physical crosslink, or a combination; wherein said crosslink is induced by an UV method, a temperature method, a pH method, an ion, or ion-radical based method or combinations thereof.
7. The method of claim 1, wherein the crystallizable molecule comprises a small organic molecule selected from a salt, urea, beta cyclodextrin, glycine and guanidine.
8. The method of claim 1, wherein the crystallizable molecule comprises potassium dihydrogen phosphate.
9. The method of claim 1, further comprising adding a cross-linking agent to the mixture, the crosslinking agent selected from group consisting of p-Azidobenzoyl hydrazide, N-5-Azido-2-nitrobenzoyloxsuccinimide, disuccinimidyl glutamate, dimethyl pimelimidate-(2)HCl, dimethyl suberimidate-2 HCl, disuccinimidyl suberate, bis[sulfosuccinimidyl suberate], l-ethyl-S-fS-dimethylaminopropy^carbodiimide-HCl, isocyanate, aldehyde, glutaraldehyde, paraformaldehyde and derivatives thereof.
10. The method of claim 1, wherein the crystal structure forms a lattice structure and supports the polymer during the crosslinking step.
11. The method of claim 1 , further comprising the step of seeding the crystal.
12. The method of claim 1, wherein the step of growing occurs by spontaneous crystal formation.
13. The method of claim 1, wherein the step of growing occurs by spontaneous crystal formation during the step of drying the cast mixture.
14. A porous hydrogel made by a method that comprises: preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel to form a cast mixture; drying the cast mixture to form an amorphous hydrogel film; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the uncrosslinked polymer around the crystal with a crosslinking agent under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel.
15. The method of claim 14, further comprising the step of seeding the cast mixture with a seed crystal of the crystallizable molecule.
16. The method of claim 14, wherein the polymer comprises nucleic acids, amino acids, saccharides, lipids and combinations thereof, in monomeric, dimeric, trimeric, oligomeric, multimeric, or polymeric forms.
17. The method of claim 14, wherein the polymer is selected from the group consisting of collagen, chitosan, gelatin, pectins, alginate, hyaluronic acid, heparin and mixtures thereof.
18. The method of claim 14, wherein the polymer comprises a biopolymer.
19. The method of claim 14, wherein the polymer is a synthetic polymer.
20. The method of claim 14, wherein the polymer is gelled by a chemical crosslink, a physical crosslink, or a combination; wherein said crosslink is induced by an UV method, a temperature method, a pH method, an ion, or ion-radical based method or combinations thereof.
21. The method of claim 14, wherein the crystallizable molecule comprises a small organic molecule selected from a salt, urea, beta cyclodextrin, glycine and guanidine.
22. The method of claim 14, wherein the crystallizable molecule comprises potassium dihydrogen phosphate.
23. The method of claim 14, further comprising adding a cross-linking agent to the mixture, the crosslinking agent selected from group consisting of p-Azidobenzoyl hydrazide, N-5-Azido-2-nitrobenzoyloxsuccinimide, disuccinimidyl glutamate, dimethyl pimelimidate-(2)HCl, dimethyl suberimidate-2 HCl, disuccinimidyl suberate, bis[sulfosuccinimidyl suberate], l-ethyl-3-[3-dimethylaminopropyl]carbodiimide-HCl, isocyanate, aldehyde, glutaraldehyde, paraformaldehyde and derivatives thereof.
24. The method of claim 14, wherein the crystal structure forms a lattice structure and supports the polymer during the crosslinking step.
25. The method of claim 14, wherein the step of growing the crystal occurs by spontaneous crystal formation.
26. A hydrogel that comprises molecular pores, the hydrogel comprising: one or more crosslinked polymers formed about a plurality of pre-formed molecular crystals, wherein the crystals are formed while the polymer is in an uncrosslinked form and the molecular crystals form a porous structure within the polymers during the crosslinking of the polymers.
27. The method of claim 26, wherein the polymer comprises nucleic acids, amino acids, saccharides, lipids and combinations thereof, in monomeric, dimeric, trimeric, oligomeric or polymeric form.
28. The method of claim 26, wherein the polymer is selected from the group consisting of collagen, chitosan, gelatin, pectins, alginate, hyaluronic acid, heparin and mixtures thereof.
29. The method of claim 26, wherein the polymer comprises a biopolymer.
30. The method of claim 26, wherein the polymer is a synthetic polymer.
31. The method of claim 26, wherein the polymer is gelled by a chemical crosslink, a physical crosslink, or a combination; wherein said crosslink is induced by an UV method, a temperature method, a pH method, an ion, or ion-radical based method or combinations thereof.
32. The method of claim 26, wherein the crystallizable molecule comprises a small organic molecule selected from a salt, urea, beta cyclodextrin, glycine and guanidine.
33. The method of claim 26, wherein the crystallizable molecule comprises potassium dihydrogen phosphate.
34. The method of claim 26, further comprising adding a cross-linking agent to the mixture, the crosslinking agent selected from group consisting of p-Azidobenzoyl hydrazide, N-5-Azido-2-nitrobenzoyloxsuccinimide, disuccinimidyl glutamate, dimethyl pimelimidate-(2)HCl, dimethyl suberimidate-2 HCl, disuccinimidyl suberate, bis[sulfosuccinimidyl suberate], l-ethyl-3-[3-dimethylaminopropyl]carbodiimide-HCl, isocyanate, aldehyde, glutaraldehyde, paraformaldehyde and derivatives thereof.
35. The method of claim 26, wherein the crystal structure forms a lattice structure and supports the polymer during the crosslinking step.
36. The method of claim 26, wherein the step of growing the crystal structure is by seeding the crystal.
37. A hydrogel made by a method comprising preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel to form a cast mixture ; allowing the cast mixture to dry to form an amorphous hydrogel film; seeding the cast mixture with a seed crystal of the crystallizable molecule; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the uncrosslinked polymer around the crystal structure under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel.
PCT/US2009/035257 2008-02-26 2009-02-26 Dendritic macroporous hydrogels prepared by crystal templating WO2009108760A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US12/919,667 US8668863B2 (en) 2008-02-26 2009-02-26 Dendritic macroporous hydrogels prepared by crystal templating
US13/909,707 US8728499B2 (en) 2008-02-26 2013-06-04 Dendritic macroporous hydrogels prepared by crystal templating
US14/277,170 US9320827B2 (en) 2008-02-26 2014-05-14 Dendritic macroporous hydrogels prepared by crystal templating
US15/135,978 US9896561B2 (en) 2008-02-26 2016-04-22 Dendritic macroporous hydrogels prepared by crystal templating
US15/890,719 US10442911B2 (en) 2008-02-26 2018-02-07 Dendritic macroporous hydrogels prepared by crystal templating
US16/597,106 US10982068B2 (en) 2008-02-26 2019-10-09 Dendritic macroporous hydrogels prepared by crystal templating
US17/231,653 US11760858B2 (en) 2008-02-26 2021-04-15 Dendritic macroporous hydrogels prepared by crystal templating
US18/361,981 US20230383086A1 (en) 2008-02-26 2023-07-31 Dendritic Macroporous Hydrogels Prepared By Crystal Templating

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3165108P 2008-02-26 2008-02-26
US61/031,651 2008-02-26

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/919,667 A-371-Of-International US8668863B2 (en) 2008-02-26 2009-02-26 Dendritic macroporous hydrogels prepared by crystal templating
US13/909,707 Continuation US8728499B2 (en) 2008-02-26 2013-06-04 Dendritic macroporous hydrogels prepared by crystal templating

Publications (3)

Publication Number Publication Date
WO2009108760A2 true WO2009108760A2 (en) 2009-09-03
WO2009108760A3 WO2009108760A3 (en) 2009-12-10
WO2009108760A8 WO2009108760A8 (en) 2010-02-04

Family

ID=41016703

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/035257 WO2009108760A2 (en) 2008-02-26 2009-02-26 Dendritic macroporous hydrogels prepared by crystal templating

Country Status (2)

Country Link
US (8) US8668863B2 (en)
WO (1) WO2009108760A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048289A1 (en) * 2010-10-08 2012-04-12 Board Of Regents, The University Of Texas System Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
WO2012048283A1 (en) * 2010-10-08 2012-04-12 Board Of Regents, The University Of Texas System One-step processing of hydrogels for mechanically robust and chemically desired features
US8668863B2 (en) 2008-02-26 2014-03-11 Board Of Regents, The University Of Texas System Dendritic macroporous hydrogels prepared by crystal templating
WO2018073235A1 (en) * 2016-10-18 2018-04-26 Aarhus Universitet Printed hyaluronic acid scaffolds
EP3505197A1 (en) 2012-12-11 2019-07-03 Board of Regents, The University of Texas System Hydrogel membrane for adhesion prevention

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101443926B1 (en) 2006-06-15 2014-10-02 마이크로벤션, 인코포레이티드 Embolization device constructed from expansible polymer
US8470035B2 (en) 2007-12-21 2013-06-25 Microvention, Inc. Hydrogel filaments for biomedical uses
US10639396B2 (en) 2015-06-11 2020-05-05 Microvention, Inc. Polymers
BR112012009287A2 (en) 2009-10-26 2017-06-06 Microvention Inc embolization device made of expandable polymer
US9456823B2 (en) 2011-04-18 2016-10-04 Terumo Corporation Embolic devices
WO2013158781A1 (en) 2012-04-18 2013-10-24 Microvention, Inc. Embolic devices
US9351993B2 (en) 2012-06-14 2016-05-31 Microvention, Inc. Polymeric treatment compositions
AU2013331439B2 (en) 2012-10-15 2016-05-12 Microvention, Inc. Polymeric treatment compositions
US11565027B2 (en) 2012-12-11 2023-01-31 Board Of Regents, The University Of Texas System Hydrogel membrane for adhesion prevention
TWI485189B (en) 2012-12-28 2015-05-21 Ind Tech Res Inst Solid form and method for preparing the same
US10124090B2 (en) 2014-04-03 2018-11-13 Terumo Corporation Embolic devices
WO2015167751A1 (en) 2014-04-29 2015-11-05 Microvention, Inc. Polymers
EP3137124B1 (en) 2014-04-29 2019-01-09 Microvention, Inc. Polymers including active agents
WO2017041068A1 (en) * 2015-09-03 2017-03-09 The Texas A & M University System Implant-based repair of osteochondral defects
EP3362266B1 (en) 2015-10-15 2021-09-01 The Regents of the University of California Apparatus and method for cryogenic 3d printing
US10449272B2 (en) 2015-10-16 2019-10-22 Industrial Technology Research Institute Hydrogel composition and method for using the same
EP3181700A1 (en) * 2015-12-18 2017-06-21 Safeguard Biosystems Holdings Ltd. Three-dimensional polymer networks with channels situated therein
US10368874B2 (en) 2016-08-26 2019-08-06 Microvention, Inc. Embolic compositions
WO2018146656A1 (en) 2017-02-13 2018-08-16 University Of Florida Research Foundation, Inc. Sharklet topographies to control neural cell interactions with implanted electrodes
US11376005B2 (en) 2017-05-24 2022-07-05 University Of Florida Research Foundation, Incorporated Tissue-engineered electronic peripheral nerve interface
EP3418741A1 (en) * 2017-06-19 2018-12-26 Safeguard Biosystems Holdings Ltd. Three-dimensional polymer networks and their use
CN108187130B (en) * 2017-09-15 2020-08-18 海宁侏罗纪生物科技有限公司 Reagent for repairing biological injury or stopping bleeding and application thereof
WO2019074965A1 (en) 2017-10-09 2019-04-18 Microvention, Inc. Radioactive liquid embolic
CA3111444A1 (en) * 2018-09-04 2020-03-12 Massachusetts Eye And Ear Infirmary Light activated adhesive scaffold
CN109294002B (en) * 2018-09-15 2021-05-04 深圳先进技术研究院 Controllable bidirectional three-dimensional deformation hydrogel film, preparation method thereof and flexible microelectrode array
WO2020051920A1 (en) * 2018-09-15 2020-03-19 深圳先进技术研究院 Controlled bidirectional three-dimensional deformation hydrogel thin film, preparation method therefor, and flexible microelectrode array
CN110698701B (en) * 2019-11-04 2023-01-13 武汉轻工大学 Low-temperature induced collagen self-assembly gel and preparation method thereof
WO2022149070A1 (en) 2021-01-05 2022-07-14 C-Care, Llc Unit dose article for adding a cosmetic function to a cosmetic base product
CN113788971A (en) * 2021-10-22 2021-12-14 华东理工大学 Deproteinized natural rubber/chitosan composite membrane and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004732A1 (en) * 1989-10-03 1991-04-18 Advanced Polymer Systems, Inc. Erodible macroporous hydrogel particles and preparation thereof
US6414043B1 (en) * 1998-06-26 2002-07-02 University Of Pittsburgh Hydrogel materials with crystalline colloidal array of watervoids for detection and macromolecule separations
US6608117B1 (en) * 2001-05-11 2003-08-19 Nanosystems Research Inc. Methods for the preparation of cellular hydrogels
US6653420B2 (en) * 2000-01-05 2003-11-25 Novartis Ag Porous hydrogels
WO2005020849A2 (en) * 2003-08-29 2005-03-10 Mayo Foundation For Medical Education And Research Hydrogel porogens for fabricating biodegradable scaffolds

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2008026A (en) 1933-10-06 1935-07-16 B F Gladding & Co Inc Package for fishing lines and the like
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4196070A (en) * 1977-12-12 1980-04-01 Nuclepore Corporation Method for forming microporous fluorocarbon polymer sheet and product
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
JPS61468A (en) 1984-06-14 1986-01-06 Fuji Electric Co Ltd Intermittent charge controlling system of electric precipitator
JPH06100468B2 (en) 1986-05-13 1994-12-12 大成建設株式会社 Measuring method of oblique hole displacement
US6610669B1 (en) * 1987-09-18 2003-08-26 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US6235726B1 (en) * 1987-09-18 2001-05-22 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US6174999B1 (en) * 1987-09-18 2001-01-16 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US6030958A (en) * 1987-09-18 2000-02-29 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US5017229A (en) * 1990-06-25 1991-05-21 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US4937270A (en) * 1987-09-18 1990-06-26 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
IT1248666B (en) 1990-05-30 1995-01-26 Fidia Spa GEL IN THE FORM OF HIGHLY HYDRATED SELF-SUPPORTING FILMS, PROCESS FOR THEIR PREPARATION AND USE IN THE THERAPY OF INJURIES AND / OR SKIN PATHOLOGIES
US5563188A (en) 1990-06-05 1996-10-08 Stankiewicz Gmbh Impact resistant coating composition
JPH04236124A (en) 1991-01-11 1992-08-25 Meidensha Corp Method for detecting small ground fault of high-voltage distribution line
US5443459A (en) 1991-01-30 1995-08-22 Alza Corporation Osmotic device for delayed delivery of agent
GR920100122A (en) 1991-04-05 1993-03-16 Ethicon Inc Ionically crosslinked carboxyl-containing polysaccharides for adhension prevention.
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
CA2120230A1 (en) * 1991-10-15 1993-04-29 Donald W. Renn .beta.-1,3-glucan polysaccharides, compositions, and their preparation and uses
AU662357B2 (en) 1991-10-18 1995-08-31 Ethicon Inc. Adhesion barrier applicator
IT1254170B (en) * 1991-12-18 1995-09-11 Mini Ricerca Scient Tecnolog COMPOSITE MEMBRANES FOR GUIDED REGENERATION OF FABRICS
US7060287B1 (en) 1992-02-11 2006-06-13 Bioform Inc. Tissue augmentation material and method
US7968110B2 (en) * 1992-02-11 2011-06-28 Merz Aesthetics, Inc. Tissue augmentation material and method
US5312333A (en) 1992-04-03 1994-05-17 United States Surgical Corporation Endoscopic material delivery device
US20040138329A1 (en) * 1992-04-20 2004-07-15 Board Of Regents Of The University Of Texas System Gels for encapsulation of biological materials
US5266326A (en) 1992-06-30 1993-11-30 Pfizer Hospital Products Group, Inc. In situ modification of alginate
JPH06100468A (en) 1992-09-25 1994-04-12 Kibun Food Chemifa Co Ltd Sustained release composition
CA2114290C (en) 1993-01-27 2006-01-10 Nagabushanam Totakura Post-surgical anti-adhesion device
US5531716A (en) * 1993-09-29 1996-07-02 Hercules Incorporated Medical devices subject to triggered disintegration
PL181064B1 (en) * 1994-03-07 2001-05-31 Dendritech Inc Biologically active and/or oriented conjugates of dendrimers
US5981825A (en) 1994-05-13 1999-11-09 Thm Biomedical, Inc. Device and methods for in vivo culturing of diverse tissue cells
GB9413931D0 (en) 1994-07-11 1994-08-31 C V Lab Ltd Alginate fabric, method of preparation and use
GB9414304D0 (en) 1994-07-15 1994-09-07 C V Lab Ltd Fibres, manufacture and use
US5834029A (en) * 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
US5531735A (en) * 1994-09-27 1996-07-02 Hercules Incorporated Medical devices containing triggerable disintegration agents
JP2891640B2 (en) 1994-09-30 1999-05-17 ナショナル住宅産業株式会社 Panel opening connection structure
US6294202B1 (en) * 1994-10-06 2001-09-25 Genzyme Corporation Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers
US5563186A (en) * 1994-11-21 1996-10-08 Thompson; Ronald G. Crosslinked alginate-based gels for matrix conformance
US20020131933A1 (en) * 1996-01-16 2002-09-19 Yves Delmotte Biopolymer membrane and methods for its preparation
US5750585A (en) * 1995-04-04 1998-05-12 Purdue Research Foundation Super absorbent hydrogel foams
US6150581A (en) 1995-06-07 2000-11-21 United States Surgical Corporation Chitosan/alginate anti-adhesion barrier
CA2224253A1 (en) * 1995-06-09 1996-12-27 Martin J. Macphee Chitin hydrogels, methods of their production and use
CA2226299A1 (en) * 1995-08-11 1997-02-27 Dendritech, Inc. Hyper comb-branched polymer conjugates
SI9620106B (en) * 1995-08-29 2005-12-31 Fidia Advanced Biopolymers Srl Bio-materials for preventing post-surgical adhesions comprised of hyaluronic acid derivatives
US5855613A (en) * 1995-10-13 1999-01-05 Islet Sheet Medical, Inc. Retrievable bioartificial implants having dimensions allowing rapid diffusion of oxygen and rapid biological response to physiological change
US5684051A (en) 1996-04-24 1997-11-04 Hercules Incorporated Medical devices with improved elastic response
IL118376A0 (en) * 1996-05-22 1996-09-12 Univ Ben Gurion Polysaccharide sponges for cell culture and transplantation
WO1997045532A1 (en) * 1996-05-28 1997-12-04 Brown University Research Foundation Hyaluronan based biodegradable scaffolds for tissue repair
US6500777B1 (en) * 1996-06-28 2002-12-31 Ethicon, Inc. Bioresorbable oxidized cellulose composite material for prevention of postsurgical adhesions
US6368356B1 (en) * 1996-07-11 2002-04-09 Scimed Life Systems, Inc. Medical devices comprising hydrogel polymers having improved mechanical properties
US6060534A (en) * 1996-07-11 2000-05-09 Scimed Life Systems, Inc. Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties
US5866554A (en) 1996-07-19 1999-02-02 Shalaby; Shalaby W. Compositions for prevention of inflammation and adhesion formation and uses thereof
ATE413415T1 (en) * 1996-09-19 2008-11-15 Univ Michigan POLYMERS CONTAINING POLYSACCHARIDES SUCH AS ALGINATES OR MODIFIED ALGINATES
EP1806367A3 (en) 1996-09-19 2007-11-28 The Regents Of The University Of Michigan Polymers containing polysaccharides such as alginates or modified alginates
US7009034B2 (en) 1996-09-23 2006-03-07 Incept, Llc Biocompatible crosslinked polymers
US5863551A (en) * 1996-10-16 1999-01-26 Organogel Canada Ltee Implantable polymer hydrogel for therapeutic uses
US5993661A (en) * 1997-04-14 1999-11-30 The Research Foundation Of State University Of New York Macroporous or microporous filtration membrane, method of preparation and use
US5984948A (en) 1997-04-14 1999-11-16 Hasson; Harrith M. Device for closing an opening in tissue and method of closing a tissue opening using the device
US6271278B1 (en) * 1997-05-13 2001-08-07 Purdue Research Foundation Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
US5906997A (en) * 1997-06-17 1999-05-25 Fzio Med, Inc. Bioresorbable compositions of carboxypolysaccharide polyether intermacromolecular complexes and methods for their use in reducing surgical adhesions
US6869938B1 (en) * 1997-06-17 2005-03-22 Fziomed, Inc. Compositions of polyacids and polyethers and methods for their use in reducing adhesions
US6184206B1 (en) 1997-09-03 2001-02-06 The Burnham Institute Integrin ligand dissociators
US6236726B1 (en) 1998-02-27 2001-05-22 Nortel Networks Limited Transmit power scaling for far-end crosstalk reduction
US6410044B1 (en) * 1998-03-19 2002-06-25 Surmodics, Inc. Crosslinkable macromers
US6007833A (en) * 1998-03-19 1999-12-28 Surmodics, Inc. Crosslinkable macromers bearing initiator groups
DE19825884A1 (en) 1998-06-10 1999-12-16 Hilti Ag Undercut dowels
US6818018B1 (en) * 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
US6514534B1 (en) 1998-08-14 2003-02-04 Incept Llc Methods for forming regional tissue adherent barriers and drug delivery systems
US7347850B2 (en) 1998-08-14 2008-03-25 Incept Llc Adhesion barriers applicable by minimally invasive surgery and methods of use thereof
DE69943297D1 (en) 1998-08-14 2011-05-05 Incept Llc APPARATUS FOR IN-SITU-EDUCATION OF HYDROGELS
US6630457B1 (en) * 1998-09-18 2003-10-07 Orthogene Llc Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same
US6841153B1 (en) * 1998-10-02 2005-01-11 University Of Florida Prevention of adhesions
DE60018814T2 (en) 1999-01-21 2006-04-06 Nipro Corp. Sewable membrane for adhesion prevention
NZ513538A (en) * 1999-02-03 2004-02-27 Powderject Res Ltd Pharmaceutical composition associated with hydrogel particles for administration by transdermal delivery from a needless syringe
DE19909214A1 (en) * 1999-03-03 2000-09-07 Basf Ag Water-absorbent, foam-like, crosslinked polymers with improved distribution effect, process for their preparation and their use
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US6767928B1 (en) * 1999-03-19 2004-07-27 The Regents Of The University Of Michigan Mineralization and biological modification of biomaterial surfaces
JP2002542326A (en) * 1999-04-09 2002-12-10 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン Manufacture of porous hydrogel products
ATE277647T1 (en) * 1999-07-28 2004-10-15 United States Surgical Corp ANTI-ADHESION LAYER MADE OF HYALURONIC ACID
US6566345B2 (en) 2000-04-28 2003-05-20 Fziomed, Inc. Polyacid/polyalkylene oxide foams and gels and methods for their delivery
JP2001212224A (en) 2000-02-04 2001-08-07 Toyobo Co Ltd Wound coating material
US6521223B1 (en) * 2000-02-14 2003-02-18 Genzyme Corporation Single phase gels for the prevention of adhesions
US6638917B1 (en) * 2000-02-25 2003-10-28 Scimed Life Systems, Inc. Reducing adhesion
JP2001259212A (en) 2000-03-15 2001-09-25 Sankyo Kk Apparatus for game
JP2001269212A (en) 2000-03-24 2001-10-02 Chikuma & Co Ltd Satchel
US6991652B2 (en) * 2000-06-13 2006-01-31 Burg Karen J L Tissue engineering composite
DE60133744T2 (en) * 2000-07-28 2009-05-14 Anika Therapeutics, Inc., Woburn BIOABSORBABLE COMPOSITE MATERIALS FROM DERIVATED HYALURONIC ACID
US6599526B2 (en) * 2000-08-18 2003-07-29 The University Of North Texas Health Science Center At Fort Worth Pericardial anti-adhesion patch
KR100451910B1 (en) 2000-10-05 2004-10-08 주식회사 바이오폴리테크 A water soluble and biodegradable polymer gel, and a process of preparing for the same
JP3418373B2 (en) 2000-10-24 2003-06-23 エヌ・アール・エス・テクノロジー株式会社 Surface acoustic wave device and method of manufacturing the same
US6660225B2 (en) 2000-12-11 2003-12-09 Advanced Materials Technologies Pte, Ltd. Method to form multi-material components
US6653240B2 (en) 2001-01-12 2003-11-25 International Business Machines Corporation FIB/RIE method for in-line circuit modification of microelectronic chips containing organic dielectric
GB0103330D0 (en) 2001-02-10 2001-03-28 Surgical Innovations Ltd Laparoscopic gel applicator
US6878384B2 (en) * 2001-03-13 2005-04-12 Microvention, Inc. Hydrogels that undergo volumetric expansion in response to changes in their environment and their methods of manufacture and use
US6913765B2 (en) * 2001-03-21 2005-07-05 Scimed Life Systems, Inc. Controlling resorption of bioresorbable medical implant material
EP1423093A4 (en) * 2001-04-23 2005-11-30 Wisconsin Alumni Res Found Bifunctional-modified hydrogels
DE10123604A1 (en) 2001-05-16 2002-11-21 Solvay Fluor & Derivate Non-flammable premix for the production of polyurethane foam products comprises binary propellant mixture and phosphorous compound
US7201917B2 (en) * 2001-07-16 2007-04-10 Depuy Products, Inc. Porous delivery scaffold and method
JP3805654B2 (en) 2001-08-29 2006-08-02 株式会社ネクスト Fine particles of biopolymers that prevent hemostasis and adhesion
US6600011B2 (en) * 2001-10-09 2003-07-29 Genzyme Corporation Process for purification and drying of polymer hydrogels
US7347988B2 (en) * 2001-11-15 2008-03-25 University Of North Texas Synthesis, uses and compositions of crystal hydrogels
US7629388B2 (en) * 2001-11-20 2009-12-08 William Marsh Rice University Synthesis and characterization of biodegradable cationic poly(propylene fumarate-co-ethylene glycol) copolymer hydrogels modified with agmatine for enhanced cell adhesion
KR20020011955A (en) 2001-12-26 2002-02-09 김정식 A conglutination inhibitor
TWI255224B (en) * 2002-01-09 2006-05-21 Novartis Ag Polymeric articles having a lubricious coating and method for making the same
US7235296B2 (en) 2002-03-05 2007-06-26 3M Innovative Properties Co. Formulations for coated diamond abrasive slurries
WO2003078159A1 (en) 2002-03-13 2003-09-25 Regents Of The University Of Minnesota Silica-based materials and methods
US20050107868A1 (en) * 2002-03-28 2005-05-19 JAPAN as represented by President of NATIONAL & CARDIOVASCULAR CENTER Scaffold for tissue engineering, artificial blood vessel, cuff, and biological implant covering member
US6960617B2 (en) * 2002-04-22 2005-11-01 Purdue Research Foundation Hydrogels having enhanced elasticity and mechanical strength properties
DE10223310A1 (en) * 2002-05-24 2003-12-11 Biotronik Mess & Therapieg Process for coating implants with a polysaccharide layer
WO2004041845A2 (en) * 2002-11-01 2004-05-21 Trustees Of Tufts College Templated native silk smectic gels
WO2004044281A2 (en) * 2002-11-12 2004-05-27 The Regents Of The University Of California Nano-porous fibers and protein membranes
US7083697B2 (en) * 2002-12-30 2006-08-01 Boston Scientific Scimed, Inc. Porous spun polymeric structures and method of making same
FR2850380B1 (en) 2003-01-23 2006-07-07 Sanofi Synthelabo ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS
FR2861734B1 (en) * 2003-04-10 2006-04-14 Corneal Ind CROSSLINKING OF LOW AND HIGH MOLECULAR MASS POLYSACCHARIDES; PREPARATION OF INJECTABLE SINGLE PHASE HYDROGELS; POLYSACCHARIDES AND HYDROGELS OBTAINED
CN101137388A (en) 2003-05-15 2008-03-05 犹他卅大学研究基金会 Anti-adhesion composites and methods os use thereof
SE0301592D0 (en) 2003-05-28 2003-05-28 Amersham Biosciences Ab Electrophoretic support
WO2005017009A1 (en) * 2003-08-15 2005-02-24 The Texas A & M University System Hydrolytically stable isoelectric hydrogel compositions
EP1664398A4 (en) * 2003-09-03 2009-08-26 Shmuel Bukshpan Methods and apparatus for rapid crystallization of biomolecules
WO2005025630A1 (en) * 2003-09-10 2005-03-24 Cato T Laurencin Polymeric nanofibers for tissue engineering and drug delivery
US20130211320A1 (en) 2003-10-07 2013-08-15 Nawar Alkhamesi System and method for delivering an anti-adhesive substance to a body cavity
EP1696974B1 (en) * 2003-12-19 2007-05-23 Basf Aktiengesellschaft Swellable hydrogel-forming polymers having a low fine dust concentration
US8002830B2 (en) * 2004-02-06 2011-08-23 Georgia Tech Research Corporation Surface directed cellular attachment
EP1742692A4 (en) 2004-03-17 2012-06-27 Genzyme Corp Anti-adhesion spraying
WO2005105172A1 (en) * 2004-04-20 2005-11-10 Genzyme Corporation Surgical mesh-like implant
US8030070B2 (en) * 2004-04-28 2011-10-04 Sanofi Pasteur Vaxdesign Corp. Artificial lymphoid tissue equivalent
US7855074B2 (en) * 2004-04-28 2010-12-21 Vaxdesign Corp. Artificial immune system: methods for making and use
US7758654B2 (en) * 2004-05-20 2010-07-20 Kensey Nash Corporation Anti-adhesion device
EP1773485B1 (en) * 2004-06-07 2015-09-16 Natrix Separations Inc. Stable composite material comprising supported porous gels
ITRM20040318A1 (en) * 2004-06-28 2004-09-28 Univ Palermo HYALURONIC AND ALPHA HYDROGEL, BETA-POLYASPARTYL HYDRAZIDE AND THEIR BIOMEDICAL AND PHARMACEUTICAL APPLICATIONS.
JP4934036B2 (en) 2004-08-17 2012-05-16 タイコ ヘルスケア グループ リミテッド パートナーシップ Anti-adhesion barrier
US8663625B2 (en) * 2004-10-15 2014-03-04 Cornell Research Foundation Diffusively permeable monolithic biomaterial with embedded microfluidic channels
US7252832B1 (en) 2004-12-13 2007-08-07 Biomet Sports Medicine, Inc. Composite collagen material and method of forming same
AU2006244714A1 (en) * 2005-05-13 2006-11-16 Protista Biotechnology Ab Macroporous hydrogels, their preparation and their use
WO2007016622A2 (en) * 2005-08-02 2007-02-08 Wright Medical Technolody, Inc. Gel composition for inhibiting cellular adhesion
KR100785378B1 (en) 2005-09-05 2007-12-14 주식회사 바이오레인 Multi-layered antiadhesion barrier
US7989505B2 (en) * 2005-09-23 2011-08-02 University Of North Texas Synthesis of columnar hydrogel colloidal crystals in water-organic solvent mixture
EP1806387B1 (en) 2005-12-07 2012-07-04 Seiko Epson Corporation Photocurable ink composition and photocurable ink set
US20070202084A1 (en) * 2005-12-14 2007-08-30 Anika Therapeutics, Inc. Bioabsorbable implant of hyaluronic acid derivative for treatment of osteochondral and chondral defects
US20100273667A1 (en) * 2006-02-10 2010-10-28 The Regents Of The University Of Michigan Cell culture well-plates having inverted colloidal crystal scaffolds
US8110242B2 (en) * 2006-03-24 2012-02-07 Zimmer, Inc. Methods of preparing hydrogel coatings
JP2009533455A (en) 2006-04-12 2009-09-17 マサチューセッツ インスティテュート オブ テクノロジー Compositions and methods for inhibiting adhesions
US7833284B2 (en) 2006-06-28 2010-11-16 The Cleveland Clinic Foundation Anti-adhesion membrane
JP2009542895A (en) * 2006-07-06 2009-12-03 アボツト・レスピラトリー・エル・エル・シー Superporous hydrogel that can withstand abuse
US20100062232A1 (en) * 2006-12-15 2010-03-11 Drexel University Multilayer films
US20080182012A1 (en) * 2007-01-31 2008-07-31 Motorola, Inc. Micro fuel cell having macroporous metal current collectors
AU2008213323B2 (en) 2007-02-06 2012-05-24 Teijin Limited Cellulose derivative and method for production thereof
US8741316B2 (en) * 2007-03-12 2014-06-03 Board Of Regents, The University Of Texas System Highly porous, recognitive polymer systems
US7504286B2 (en) 2007-03-28 2009-03-17 Advanced Micro Devices, Inc. Semiconductor memory devices and methods for fabricating the same
US7998380B2 (en) * 2007-07-13 2011-08-16 Wisconsin Alumni Research Foundation Method of fabricating a tissue engineering scaffold
US20090062233A1 (en) * 2007-08-09 2009-03-05 Xin Ji Modified starch material of biocompatible hemostasis
US8075908B2 (en) 2007-08-17 2011-12-13 Anhese Llc Apparatus and method for reducing the occurrence of post-surgical adhesions
US20120070473A1 (en) 2007-08-17 2012-03-22 Anhese Llc Apparatus and Method for Reducing the Occurrence of Post-Surgical Adhesions
CA2709546C (en) 2007-08-28 2017-09-26 Theodore Athanasiadis Surgical hydrogel
US7919542B2 (en) * 2007-11-12 2011-04-05 Zimmer Spine, Inc. Phase separated, branched, copolymer hydrogel
AU2008346830B2 (en) 2007-12-31 2014-07-24 Acclarent, Inc. Mucosal tissue dressing and method of use
WO2009108760A2 (en) 2008-02-26 2009-09-03 Board Of Regents, The University Of Texas System Dendritic macroporous hydrogels prepared by crystal templating
US20090294049A1 (en) 2008-06-02 2009-12-03 Medtronic Vascular, Inc. Biodegradable Adhesive Hydrogels
US8551136B2 (en) 2008-07-17 2013-10-08 Actamax Surgical Materials, Llc High swell, long-lived hydrogel sealant
US20100015231A1 (en) 2008-07-17 2010-01-21 E.I. Du Pont De Nemours And Company Low swell, long-lived hydrogel sealant
FR2937857B1 (en) 2008-10-30 2015-04-03 Brothier Lab SURGICAL MEMBRANE ANTIADHERENCE
WO2010054068A2 (en) 2008-11-10 2010-05-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cyclic adenosine monophosphates for reducing the formation of adhesions
US9622481B2 (en) 2009-01-23 2017-04-18 Kane Biotech Inc. Biofilm-removing antimicrobial compositions and uses thereof
US9592108B2 (en) 2009-07-29 2017-03-14 Covidien Lp System and method of laparoscopic use of hemostatic patch
CA2780919A1 (en) 2009-10-21 2011-04-28 Bayer Materialscience Ag Biodegradable hydrogel
KR20090130277A (en) 2009-11-29 2009-12-22 이정삼 The special mesh used in one port laparoscopic hernia operation
EP2552457B1 (en) 2010-03-30 2015-07-29 Histocell, S.L. Biomaterial from wharton's jelly umbilical cord
US20130034592A1 (en) 2010-04-22 2013-02-07 Teijin Limited Hydrogel
CN103189035A (en) 2010-08-16 2013-07-03 瑞士商麦斯特医疗股份有限公司 Anti-adhesion alginate barrier of variable absorbance
JP6042815B2 (en) 2010-10-08 2016-12-14 ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム Anti-adhesion barrier membranes using alginate and hyaluronic acid for biomedical applications
WO2012057381A1 (en) 2010-10-29 2012-05-03 주식회사 휴메딕스 Adhesion barrier containing hyaluronic acids and l-arginine
US8404256B2 (en) 2011-05-06 2013-03-26 The University Of Memphis Research Foundation Biomaterial composite composition and method of use
JPWO2012165462A1 (en) 2011-05-31 2015-02-23 国立大学法人 東京大学 Hydrogel and method for producing the same
KR101330652B1 (en) 2012-02-28 2013-11-18 (주)시지바이오 Anti―adhesion polymer composition able to load growth factors
DE102012104530A1 (en) 2012-05-25 2013-11-28 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Use of a biocompatible composition
KR101766679B1 (en) 2012-12-11 2017-08-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Hydrogel membrane for adhesion prevention
US9990917B2 (en) 2015-04-13 2018-06-05 Intel Corporation Method and system of random access compression of transducer data for automatic speech recognition decoding

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004732A1 (en) * 1989-10-03 1991-04-18 Advanced Polymer Systems, Inc. Erodible macroporous hydrogel particles and preparation thereof
US6414043B1 (en) * 1998-06-26 2002-07-02 University Of Pittsburgh Hydrogel materials with crystalline colloidal array of watervoids for detection and macromolecule separations
US6653420B2 (en) * 2000-01-05 2003-11-25 Novartis Ag Porous hydrogels
US6608117B1 (en) * 2001-05-11 2003-08-19 Nanosystems Research Inc. Methods for the preparation of cellular hydrogels
WO2005020849A2 (en) * 2003-08-29 2005-03-10 Mayo Foundation For Medical Education And Research Hydrogel porogens for fabricating biodegradable scaffolds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JULIANA MATOS SEIDEL ET AL.: 'Synthesis of polyHEMA hydrogels for using as biomaterials. Bulk and solution radical- initiated polymerization techniques.' MATERIALS RESEARCH. vol. 3, no. 3, July 2000, ISSN 1516-1439 *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10982068B2 (en) 2008-02-26 2021-04-20 Board Of Regents, The University Of Texas System Dendritic macroporous hydrogels prepared by crystal templating
US8728499B2 (en) 2008-02-26 2014-05-20 Board Of Regents, The University Of Texas System Dendritic macroporous hydrogels prepared by crystal templating
US11760858B2 (en) 2008-02-26 2023-09-19 Board Of Regents, The University Of Texas System Dendritic macroporous hydrogels prepared by crystal templating
US10442911B2 (en) 2008-02-26 2019-10-15 Board Of Regents, The University Of Texas System Dendritic macroporous hydrogels prepared by crystal templating
US9320827B2 (en) 2008-02-26 2016-04-26 Board Of Regents, The University Of Texas System Dendritic macroporous hydrogels prepared by crystal templating
US8668863B2 (en) 2008-02-26 2014-03-11 Board Of Regents, The University Of Texas System Dendritic macroporous hydrogels prepared by crystal templating
US9896561B2 (en) 2008-02-26 2018-02-20 Board Of Regents, The University Of Texas System Dendritic macroporous hydrogels prepared by crystal templating
JP2013544549A (en) * 2010-10-08 2013-12-19 ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム Anti-adhesion barrier membranes using alginate and hyaluronic acid for biomedical applications
US11246937B2 (en) 2010-10-08 2022-02-15 Board Of Regents, The University Of Texas System One-step processing of hydrogels for mechanically robust and chemically desired features
US9095558B2 (en) * 2010-10-08 2015-08-04 Board Of Regents, The University Of Texas System Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
US20160015866A1 (en) * 2010-10-08 2016-01-21 Board Of Regents, The University Of Texas System Anti-Adhesive Barrier Membrane Using Alginate and Hyaluronic Acid for Biomedical Applications
US10314950B2 (en) 2010-10-08 2019-06-11 Board Of Regents, The University Of Texas System Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
US9656001B2 (en) 2010-10-08 2017-05-23 Board Of Regents, The University Of Texas System Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
EP2624874A4 (en) * 2010-10-08 2014-04-02 Univ Texas Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
US20120088832A1 (en) * 2010-10-08 2012-04-12 Board Of Regents, The University Of Texas System Anti-Adhesive Barrier Membrane Using Alginate and Hyaluronic Acid for Biomedical Applications
WO2012048283A1 (en) * 2010-10-08 2012-04-12 Board Of Regents, The University Of Texas System One-step processing of hydrogels for mechanically robust and chemically desired features
US10279042B2 (en) 2010-10-08 2019-05-07 Board Of Regents, The University Of Texas System One-step processing of hydrogels for mechanically robust and chemically desired features
US11890344B2 (en) 2010-10-08 2024-02-06 Board Of Regents, The University Of Texas System One-step processing of hydrogels for mechanically robust and chemically desired features
US11857701B2 (en) 2010-10-08 2024-01-02 Board Of Regents, The University Of Texas System Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
EP2624874A1 (en) * 2010-10-08 2013-08-14 Board Of Regents, The University Of Texas Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
US20190314558A1 (en) * 2010-10-08 2019-10-17 Board Of Regents, The University Of Texas System Anti-Adhesive Barrier Membrane Using Alginate and Hyaluronic Acid for Biomedical Applications
WO2012048289A1 (en) * 2010-10-08 2012-04-12 Board Of Regents, The University Of Texas System Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
US11058802B2 (en) 2010-10-08 2021-07-13 Board Of Regents, The University Of Texas System Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
US8946194B2 (en) 2010-10-08 2015-02-03 Board Of Regents, University Of Texas System One-step processing of hydrogels for mechanically robust and chemically desired features
US11744926B2 (en) 2010-10-08 2023-09-05 Board Of Regents, The University Of Texas System Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
EP4253454A2 (en) 2012-12-11 2023-10-04 Board of Regents, The University of Texas System Hydrogel membrane for adhesion prevention
EP3505197A1 (en) 2012-12-11 2019-07-03 Board of Regents, The University of Texas System Hydrogel membrane for adhesion prevention
WO2018073235A1 (en) * 2016-10-18 2018-04-26 Aarhus Universitet Printed hyaluronic acid scaffolds
CN109996566A (en) * 2016-10-18 2019-07-09 奥尔胡斯大学 The hyaluronic acid scaffold of printing

Also Published As

Publication number Publication date
US10982068B2 (en) 2021-04-20
US9320827B2 (en) 2016-04-26
US10442911B2 (en) 2019-10-15
US20110008442A1 (en) 2011-01-13
US8668863B2 (en) 2014-03-11
US20140242126A1 (en) 2014-08-28
WO2009108760A8 (en) 2010-02-04
US20200062919A1 (en) 2020-02-27
US20160237235A1 (en) 2016-08-18
US8728499B2 (en) 2014-05-20
US20180163012A1 (en) 2018-06-14
US9896561B2 (en) 2018-02-20
US20130266618A1 (en) 2013-10-10
WO2009108760A3 (en) 2009-12-10
US20210238379A1 (en) 2021-08-05
US20230383086A1 (en) 2023-11-30
US11760858B2 (en) 2023-09-19

Similar Documents

Publication Publication Date Title
US11760858B2 (en) Dendritic macroporous hydrogels prepared by crystal templating
Reakasame et al. Oxidized alginate-based hydrogels for tissue engineering applications: a review
Huan et al. Low solids emulsion gels based on nanocellulose for 3D-printing
Naseri et al. Nanocellulose-based interpenetrating polymer network (IPN) hydrogels for cartilage applications
Huang et al. Effects of chitin whiskers on physical properties and osteoblast culture of alginate based nanocomposite hydrogels
Omar et al. Supramolecular hydrogels: Design strategies and contemporary biomedical applications
Nakamatsu et al. Processing and characterization of porous structures from chitosan and starch for tissue engineering scaffolds
US20220160877A1 (en) One-Step Processing of Hydrogels for Mechanically Robust and Chemically Desired Features
Costa et al. Compact saloplastic membranes of natural polysaccharides for soft tissue engineering
Yu et al. Evaluation of a polyvinyl alcohol‐alginate based hydrogel for precise 3D bioprinting
Zawko et al. Crystal templating dendritic pore networks and fibrillar microstructure into hydrogels
do Nascimento et al. Cellulose nanocrystals-reinforced core-shell hydrogels for sustained release of fertilizer and water retention
Xu et al. Cornea-stroma-mimicking films derived from cellulose nanocrystal templating fibrous collagen as therapeutic contact lenses
Taneja et al. Hydrogel based 3D printing: Bio ink for tissue engineering
Li et al. Creating ultrastrong and osteogenic chitin nanocomposite hydrogels via chitin whiskers with different surface chemistries
Zhu et al. Chitin whiskers enhanced methacrylated hydroxybutyl chitosan hydrogels as anti-deformation scaffold for 3D cell culture
Sadhasivam et al. Biocompatible porous scaffolds of chitosan/poly (EG-ran-PG) blends with tailored pore size and nontoxic to Mesenchymal stem cells: preparation by controlled evaporation from aqueous acetic acid solution
Farrukh et al. Synthesis and applications of carbohydrate-based hydrogels
Čadež et al. Calcium phosphate and calcium carbonate mineralization of bioinspired hydrogels based on β-chitin isolated from biomineral of the common cuttlefish (Sepia officinalis, L.)
Schmidt et al. Dendritic macroporous hydrogels prepared by crystal templating
JP4017958B2 (en) Cell culture carrier
Johnson Crosslinking and Characterization of Pressurized Gas Expanded Liquid Polymer Morphologies to Create Macroporous Hydrogel Scaffolds for Drug Delivery and Wound Healing
Zawko Hyaluronic acid hydrogel materials
Li et al. Construction of chitosan-gelatin polysaccharide-protein composite hydrogel via mechanical stretching and its biocompatibility in vivo
Rana et al. Effect of radiation on Hydroxyapatite-Chitosan-Gelatin-Agarose scaffold for bone tissue regeneration.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09715061

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12919667

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09715061

Country of ref document: EP

Kind code of ref document: A2